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1.1. Immunological memory is long-lived after infection 
or vaccination 
The generation and the maintenance of a serological memory are fundamental for 
the immune system to remember the pathogens to which it was exposed. It has 
been so far demonstrated that a successful response remains in human sera for a 
lifetime after vaccination or infections (Amanna IJ1, 2006 Jun; Hammarlund E1, 
2003 Sep).  Different are the hypotheses suggested in the recent years to explain 
the mechanisms at the basis of such durable responses and it is noteworthy that all 
these hypotheses rely upon the establishment of a pool of Antigen-specific 
Plasmablasts (PBs) and Memory B cells (MBCs) (Mark K. Slifka, 1998; Traggiai 













PBs are known to be the main source of antigen specific antibodies and these 
terminally differentiated B cells are able to maintain antibody level independently 
(Slifka MK1, 1998 ) or could require a refilling mediated by the continuous 
differentiation of MBCs  into PBs (Amanna IJ1, 2006 Jun; Traggiai E1, 2003 Jun 






1). Several are in fact the studies that supposed a requirement of MBCs for the 
antibody maintenance even if it seems that it is not likely to be a global mechanism 
for antibody maintenance (Ian J. Amanna, November 8, 2007).  
Both PBs and MBCs are the result of adaptive immune responses. The adaptive 
capabilities of B cells strongly rely on two independent stages of development. The 
first one occurs in the bone marrow and is an antigen-independent process by 
which each B cells finally creates a unique receptor for recognition of pathogens. 
As a consequence, a large repertoire of antigen receptors is generated with the 
potential to specifically recognize many different pathogens. The naïve B cells 
generated in this way reach the secondary lymphoid organs where they eventually 
recognize eliciting agents. Following antigen recognition, the second stage of B 
cell development starts which is antigen-dependent and leads to the clonal 
expansion and receptor affinity maturation of the antigen-activated B cells. These 
latter events are the basis for generating effector cells that elicit strong response 
and long term memory in the form of MBCs and PBs (Figure 1). 
 
1.2. Antigen-independent B cell differentiation in the 
bone marrow 
In humans the development of B cells occurs in the bone marrow proceeding 
through different stages of maturation. It has been so far demonstrated that both the 
development and function of B cells critically depend on the B-cell antigen 
receptor (BCR) (Figure 2). In its simplest form, the BCR is a heterotetramer 
composed by two identical heavy chains (HCs) and two identical light chains 
(LCs). Each chain has a variable domain at its N-terminal end a constant region at 
its C-terminal end. The first step of BCR generation is the biosynthesis of the 
Variable domain and occurs in a pre-B cell state, when a random recombination 






place at the DNA genomic level (Tonegawa, 1983). The rearranged VDJ genes, 
together with one Heavy Constant gene (for the heavy chain) or the rearranged VJ 
and Kappa or Lambda Constant genes (for the light chain) are transcribed as a pre-
messenger RNA, then spliced and translated to obtain a heavy or a light chain, 
respectively. This step is followed by the combinatorial pairing of the heavy and 
light chains. All these steps are responsible for generating the broad diversity in the 
repertoire of the final BCR. The random process of genes recombination introduces 
or subtracts nucleotides at the joints between different gene segments, while at later 
stages the combinatorial pairing of the different possible combinations of heavy- 
and light-chain V regions forming the binding site of the immunoglobulin 
molecules increases further the repertoire’s diversity. The variable antibody 
repertoire generated through these events is able to recognize both an enormous 
number of foreign antigens and the majority of the organism’s self-tissues 
molecules. 
 
Figure 2_Maturation stages of B cell development in the bone marrow (From “The 






1.3. Variations in the IG germline repertoire  
Genes encoding for the Immunoglobulins (IG) are located at three primary loci in 
the human genome and specifically: IGH at 14q32.33, IGK at 2p11.2 and IGL 
22q11.2 (Lefranc M-P, 2001). Each locus is composed by V, (D), J and C genes. 
The complete sequence of the human IGH locus has been reported for the first time 
by Matsuda et al. (Matsuda F, 1998) and comprised 44 functional/open reading 
frame (ORF) V genes, 85 pseudogenes, 27 D genes (whose 23 were functional) and 
9 J genes (6 of which were functional). This full sequence was used by the 
international ImMunoGeneTics information system (IMGT) to determine the first 
official nomenclature of the IGH genes approved by the HUGO Nomenclature 
Committee (HGNC) in 1999. After this milestone and following sequencing of 
specific germline IGHV, IGHD and IGHJ genes and expressed IGHV gene 




Figure 3_The number of known alleles for each of the mapped and unmapped 






At least 55 functional/ORF IGHV genes are known and they are grouped in seven 
phylogenetically related subgroups (IGHV1 to IGHV7). The repertoire size of each 
of the seven subgroups is variable and ranges from 1 functional gene in subgroup 
IGHV6 to 24 genes in subgroup IGHV3. In this context further variability is 
generated by the difference observed in gene allelic richness among genes, even if 
knowledge about inter-allelic variations is still incomplete due to the paucity of 
studies investigating this aspect (Figure 3). Another aspect to take into account is 
the segmental duplication in the IGH locus, i.e. the presence of repetitive IGHV 
gene-containing segments occurring multiple times across the locus, which is 
thought to be responsible of the occurrence of large insertion/deletion variants in 
the region and of the Copy Number Variation (CNV) polymorphism in the IGH 
locus (Matsuda F, 1998).  
 
1.4. Central and Pheripheral human B cell development 
Ig can be produced as membrane bound receptors (i.e. the BCR), or secreted as 
antibodies during a humoral response. The N-terminal of each heavy and light 
chain is involved in antigen binding and the C-terminal determines the class of 
antibody and mediates effector functions (Kracker, 2004) (Figure 4). The two 
different C-terminal domains of the transmembrane and secreted forms of IgHC are 
encoded by separate exons of the heavy-chain constant regions (CH) gene: the 
membrane-coding (MC) sequence that encodes the transmembrane region and its 
cytoplasmic tail, and a secretion-coding (SC) sequence that encodes the carboxy 
terminus of the secreted form. The production of the two forms is the result of an 
alternative RNA processing of the initial transcript. Different CHs, which 
determine the class or isotype of the antibody and thus its effector functions, are 
encoded by separated genes at the HC locus. The five main isotypes of 
immunoglobulin are IgM, IgD, IgG, IgE, and IgA. In humans, IgG antibodies can 






to their abundance in serum), whereas IgA antibodies are found as two subclasses 
(IgA1 and IgA2). IgM forms pentamers in serum, which accounts for its high 





























Within the variable part of both heavy and light 
chains, three regions are key for antigen 
recognition. These are termed complementarity-
determining region (CDR) 1, 2 and 3. The 
nucleotide sequence encoding the CDRs is 
particularly variable compared to the 
surrounding sequences which are termed 
framework regions. CDR1 and 2 are encoded 
within the VH-gene segment. CDR3 comprises 
the entire joint region spanning from the 
conserved cysteine in the 3’-end of the VH-gene 
to the conserved tryptophan in 5’-end of the JH-
gene.  Framework residues, that represent 
about 85% of the V region, define the 
positioning of the CDRs so that the CDRs form three loops exposed on the surface 
of the chain and create a dock for antigen binding (Figure 5).  The rearrangements 
of V(D)J gene segments take place at the late pro-B cell stage. They are rearranged 
together by the RAG1 and RAG2 enzymes, which recognize, bind and cleave 
specific recombination signalling sequences (RSS) flanking each VH-, D- and JH-
gene segment (Max, 1979; Oettinger, 1990). The RSS is composed of a relatively 
conserved heptamer (5’-CACAGTG-3’) separated from a conserved nonamer (5’-
ACAAAAACC-3’) by a non-conserved spacer region of either 12 or 23 nucleotides 
(Ramsden, 1994). Generally, a gene segment flanked by a 23-spacer RSS only 
joins with a gene segment flanked by a 12-spacer RSS. This is known as the 12/23 
rule. On the IgH locus VH- and JH gene segments are flanked by 23-spacer RSS, 
while D-gene segments are flanked by 12- spacer RSS. This arrangement ensures 
that the gene segments are associated in the correct VHDJH configuration (Early, 
1980). The first rearrangement occurs between a D- and a JH-gene segment, then a 
Figure 4_Figure 5. IgH variable 
domain structure. 







VH gene segment rearranges to the DJH rearrangement. If the initial VHDJH-
rearrangement is functional, further rearrangements on the other chromosome are 
inhibited. This mechanism, known as allelic exclusion, prevents each single B cell 
from expressing more than one type of BCR (Alt, 1984). When a VHDJH-
rearrangement is transcribed it will pair with a surrogate light chain (SL), leading to 
the assembly of a pre-BCR that will be transported to the surface membrane of 
large pre-B cells (Min Zhang, 2004). Pre-BCR expression is the first vital 
checkpoint in B cell development and marks the transition from pro- to pre-B cell. 
Shortly after pre-BCRs have been exposed on the cell surface, several signalling 
cascades (Syk- and Akt-dependent) are activated modulating the expression of rag 
genes (U. Grawunder, 1995) and inhibiting further RAG-mediated rearrangement 
in the IgH gene locus. Signalling through the pre-BCR also stimulates cell 
proliferation, and differentiation to small post-mitotic pre-B cells that start 
rearranging the IgL chain genes. The variable part of the light chain is composed of 
a VL- and JL-gene segment. The VL-gene segments are flanked by 23-spacer RSSs 
and JL-gene segment by 12- spacer RSSs. If the VLJL-rearrangement is 
translatable, it will replace the surrogate IgL chain in the pre-PCR. This step 
constitutes the second checkpoint in early B cell development and marks the 
transition from pre-B cell to immature B cell.  
Before leaving the bone marrow, immature B cells are also tested for self-
tolerance: immature B cells whose BCRs bind with high affinity to the 
‘housekeeping’ molecules expressed in the bone marrow cells (and thus are 
potentially autoreactive) receive an intracellular signal to halt their development; 
those B cells that do not recognize such molecules leave the bone marrow as naïve 
B cells reaching the peripheral blood and secondary lymphoid tissues. Naïve B 
cells recirculating in the blood and co-expressing surface bound Immunoglobulin 
M (IgM) and D (IgD) BCRs are susceptible to face different fates based on the 






typically results in an immune response that kills, clears, or neutralizes the invader.   
The ability of the immune system to respond more rapidly and effectively to 
antigens encountered previously, also referred as immunological memory, reflects 
the presence of clonally expanded populations of antigen-specific B and T 
lymphocytes. Memory immune responses are generally different from primary 
responses in terms of quality and kinetics. In fact, in secondary immune responses 
antibodies are produced faster and have a higher affinity for the antigen in respect 
to previous response. Thus immune memory resides both in the antibody that 
continues to be made and in the B cells and T cells that can rapidly interact to 
reproduce successful responses.  
It is well established that the affinity maturation of the antibody repertoire and the 
isotype switch is associated with T cell-dependent antibody responses (TD), which 
strongly rely on the cognate guidance of T follicular helper cells (TFH cells) and 
other accessory cells following initial priming and secondary challenge with 
antigen. During TD responses B cell differentiation occurs through two different 
pathways. The initial priming of naive B cells and subsequent cognate contact with 
TFH cells initiates immunoglobulin class switching that results in the rapid 
differentiation of some B cells into Antibody Secreting Cells, also called short-
lived Plasma cells, outside the B cell follicles of the secondary lymphoid organs. 
The initial B cell–T cell contact is also required to induce the formation of 
specialized areas of the secondary lymphoid organs, called Germinal Centers (GCs) 
(IC., 1994). GCs are the unique documented sites for coupling the diversification of 
BCR V gene sequences, with the selective expansion of those variants with 
improved binding affinity for antigen. In GCs, B cells activated by antigen-
recognition start to proliferate rapidly and switch on a tightly regulated nuclear 
machinery leading to the generation of a multitude of clones carrying modified 
immunoglobulin BCRs (Figure 6). In this context the Activation-induced cytidine 






2002); by deaminating deoxycytidine residues on DNA, AID paves the way to the 
introduction of point mutations, deletions and duplications in the germ-line 
sequence of the V,D,J gene segments encoding for the variable region of 
Immunoglobulins (IgV). Since Immunoglobulins bind to antigens through their 
IgV domains, this process, named Somatic HyperMutation (SHM), modulate, and 
might eventually re-shape, the specificity and overall binding affinity of the 
individuals’ repertoire of B cells and secreted antibodies. In addition, AID activity 
is also involved in the initiation of the gene-re-arrangements required to switch the 
immunoglobulin constant region to a different class (IgG, IgA or IgE) best 
mediating specific immune responses (e.g. complement activation, 













Figure 6_ T cell-dependent activation of B cells leads to the formation of GC in 
secondary lymphoid organs. Inside the GC, BCR is modified by Somatic 
HyperMutation and Class Switching. Both these events drive the differentiation of 






Inside the GC proliferating B cells compete for antigen binding and access to 
survival signals delivered by T cells. Ultimately, this race ends with the survival of 
the clones that having acquired improved antigen-binding capacity will out-
compete the others, which instead will die by neglect. While clonally expanded B 
cells are generated and selected, some of them differentiate into plasma cells that 
secrete antibodies whilst others will rest and become memory B cells that 
recirculate in the blood and will rapidly respond to subsequent antigenic re-
stimulation. Ag-specific PBs and MBCs start to populate the human blood after 
infection or vaccination in different timeslots and with different kinetics. PBs, 
representing the early component of host defence, peak in the blood around day 8 
after vaccination and return quickly to undetectable levels thereafter. Otherwise, 
Ag-specific MBCs circulate at enriched frequency in the blood peaking at 1 month 
after vaccination, and contracting slightly above or equal to baseline thereafter. 
Even if it is still controversial, there are several emerging evidences that Ag-
specific PBs and MBCs undergo affinity maturation also without GC formation in 
extra-follicular pathways. It seems that of the B cells remaining in the outer follicle 
in the early stages of the B cell response, some migrate out and establish the foci of 
short lived Plasma cells, whereas others may be the B cells that are the origin of 
GC-independent memory (Tarlinton, 2012; David Tarlinton, 2013).  
 
1.5. Diversity of B-cell memory 
A substantial fraction of B cells in humans has encountered antigen and shows 
hallmarks of B-cell memory. One of these memory B cell hallmark is considered 
the expression of CD27 (Agematsu K, 1997), but recent studies have demonstrated 
that also CD27- cells can present with an activated phenotype and molecular signs 
of antigen experience (Fecteau JF, 2006; Cagigi A, 2009), suggesting that they 






adults is derived from GC dependent reactions. The earliest GC responses generate 
IgM+ cells. It has been demonstrated that these cells can undergo subsequent class 
switching, mostly to IgG, and clonally related IgM+ and IgG+ cells can be found in 
human GCs and blood (Seifert M, 2009). IgA+ and IgG+ GC-derived memory B 
cells occur later in the course of an immune response and carry high loads of SHM.  
Terminal differentiation and survival of plasma cells 
Plasma cells are derived from activated B cells through a different transcriptional 
program than memory B cells. Since plasma cells progressively loose membrane 
BCR expression while maturing, they depend on other mechanisms for survival. 
While most plasma cells are generated in lymphoid organs and long-lived plasma 
cells reside in bone marrow (Rozanski CH, 2011), small numbers can be found 
circulating in blood of healthy adults and the latter ones have high CD38, CD27 
expression levels. Despite their low numbers in blood (1-5 cells/μl), plasma cells 
display large phenotypic heterogeneity. Interestingly, circulating IgA+ plasma cells 
are more frequent than IgM+ or IgG+. These IgA+ plasma cells display 
characteristics suggestive of a mucosal origin. 
 
1.6. Tools to dissect the human BCR repertoire  
Since the acquired immunity generates highly specific and long-lived antibody 
response, there is a growing interest in set up methodologies that can dissect this 
aspect of immune memory. It is clear that the specificity of the antibody responses 
for particular pathogens is achieved by the development of a vast diverse repertoire  
resulted by the recombination of the V-genes that finally enable antibodies 
recognizing an enormous numbers of potential epitopes.   
To summarize, after this brief excursus on the B cell development, five are the 
principal mechanisms that mediate the diversity in the antigen combining site of the 
BCR repertoire; the first three mechanisms acting at immature B cell level whereas 






1. Combinatorial diversity generated by V(D)J recombination, 
2. Junctional diversity at the recombination sites of the V(D)J genes, 
3. Random pairing of heavy and light chains to form the antigen binding site 
(Figure 7A); 
4. Somatic hypermutation that introduces point mutation into the variable 
domain,  
5. Class switch recombination that enables to change the isotypes and thus to 























Figure 7_Mechanisms that mediate the diversity in the antigen combining site of 
the BCR repertoire. A) V(D)J recombination, Juntional diversity and VH/VL 
pairing; B) Generation of different variants by SHM and CSR after GC reaction 






Due to the importance of gaining insights on the BCR nature, different progresses 
have been done to dissect the Ab repertoire. The earliest studies were performed by 
using isoelectric focusing of Antibodies on polyacrylamide gel resolving the Abs 
into pattern of bands based on their isoelectric pH values (al, 1968). From this 
study, different steps forward have been done especially with the use of PCR, 
electrophoresis and sequencing methods for determining the exact nucleotide 
sequences that encode for specific antibodies (al, 1978). These studies paved the 
way to a huge number of studies addressing the study of the repertoire and making 
use of this information to produce human monoclonal antibodies with a defined 
specificity. Three are the main strategies used to dissect the repertoire that have 
also been used to produce human monoclonal antibodies: 
1. Phage display technologies_ Phage display libraries have been 
constructed from IgV of vaccinated or infected subjects by sorting 
memory B cells and total peripheral blood mononuclear cell (PBMCs) 
populations containing all B cell subsets. Once B cells are isolated a 
random RT-PCR of VH and VL follows creating a combinatorial library 
of random VH and VL that can be expressed as single-chain variable 
antibody fragments (scFvs) on phage or antigen-binding fragments 
(Fabs) on yeast or mammalian cells (Figure 8). In this way a multitude 
of monoclonal antibodies with different specificities can be obtained 
and in fact this strategy has been used to isolate neutralizing antibodies 
specific for different numbers of pathogens such as West Nile virus, 
rabies virus, severe acute respiratory syndrome (SARS) virus, hepatitis 
A virus, HIV, hantavirus, Ebola virus, yellow fever virus, hepatitis C 
virus, measles virus and human and avian influenza virus strains, and so 
on.  Even if this methodology has been an high-throughput way to 
produce antibodies, this is not the best way to obtain information about 






the random pairing of immunoglobulin heavy and light chain variable 
regions that are cloned separately. Even if this random pairing enables 
to create a greater diversity of antibodies and it is a helpful strategy to 
generate higher affinity antibodies, it is not possible to obtain 
information about the process of affinity maturation that a given heavy 
and light chain pair went through. 
 
 
2. B cell immortalization_ this methodology generally involves culturing 
total PBMCs or sorted IgG+ memory B cells from fresh or frozen 
samples in the presence of the Epstain Barr Virus (EBV), that can 
transform all pheripheral resting B cells subsets, together with Toll Like 
Receptor 9 (TLR9) and/or allogeneic irradiated mononuclear cells to 
provide co-stimulatory signals. Under these conditions, B cells are 
induced to proliferate and to secrete antibodies. After several days, 
supernatants from cultured cells are tested for antigen binding and/or 
functional activity. The B cells producing the antibodies of interest are 
cloned by limiting dilution and further screened for the desired 
reactivity at the single-cell level before individual VH and VL are 
cloned and sequenced (Traggiai, 2012) (Figure 9). By applying this 
Figure 8_Scheme of the different steps to generate phage display libraries 






strategy the EBV-transformed B cell clones obtained can also be fused 
with myeloma cells to generate hybridomas, which facilitate the stable 
production of high levels of antibodies. This approach offers the 
opportunity to immortalize and obtain information about the antibodies 
produced from the pool of the antigen specific memory B cells. 
 
 
3. Single cell analysis of BCR repertoire_ An important advance in the 
study of the human BCR repertoire is represented by the single-cell 
reverse transcription PCR (RT-PCR) to isolate and amplify the cognate 
VH and VL genes from single B cells sorted by FACS (Thomas Tiller, 
2008; Hua-Xin Liao, 2009) (Figure 10). This kind of approach enables 
to take a snapshot of the exact repertoire of the BCR expressed on the 
surface of particular B cells in a defined time slot. By using this 
approach information can be obtained also from rare, highly discrete B 
Figure 9_Scheme of the different steps required for human B cell 
immortalization 
Figure 9_Scheme of the different steps required for human B cell 






cell subpopulations, such as MBCs, if those cells can be identified by 
FACS. This approach was firstly applied by Wardemann et al. to 
understand the tolerogenic selection of developing human B cell 
subpopulations. Thereafter, this strategy has been applied to investigate 
the different type and class of B cells in healthy, or 
immunocompromised individuals, or to study the repertoire of PBs and 
MBCs elicited by vaccination. There are a lot of studies focused on the 
repertoire of PBs isolated 7 days after vaccination because they are the 
first and robust source of antigen specific B cells and also because their 
identification by FACS basically relies upon the expression of Cluster 
of Differentiation (CD) surface markers. Moreover, since the time of 
antigen exposure is well defined, their dissection is particularly useful 
for examining the ongoing immune response to vaccines. For example, 
this method has been successful for analyzing the immune response to 
influenza, tetanus and anthrax vaccination. To a lesser extent also the 
repertoire of antigen-specific MBCs has been dissected. However the 
paucity of studies on this direction is ascribed to the lack of suitable 
tools for the identification of antigen specific Memory B cells, which 
circulate at very low frequencies in the blood as well as to the low 
efficiency in the recovery of VH and VL genes after RT-PCR.  The 
identification of Ag-specific B cells has been so far challenging but 
several efforts have been done to solve this issue and one solution came 
from our laboratory (Bardelli M, 2013). All these studies basically rely 
on the use of fluorescent antigen baits or antigen tetramers to identify 
memory B cells engaged into BCR-specific interactions. Brightly 
labelled memory B cells are identified and isolated as single cells on a 
96-well plate containing a lysis buffer that preserve mRNA. Thereafter, 









Finally, various high-throughput technologies are emerging to generate a more 
comprehensive picture of the human B cell response. One promising approach is 
the use of next-generation sequencing to exhaustively sequence the entire B cell 
repertoire. The application of high throughput sequencing of paired VH and VL 
sequences to different B cell subsets isolated overtime following vaccination could 
be key to understand the specificity, the frequency and also the class of memory 
cells required to mediate protection, as well as the individual variability in the 
breadth of the response. Moreover, this analysis could be helpful in discriminating 
useless versus harming responses and thus to design better vaccine antigens able to 
stimulate and guide successful immune memory responses.    
Figure 10_Schematic representation of scPCR approach to dissect changes 






2.1. Classification of influenza viruses  
Influenza viruses are members of the Orthomyxoviridae family (R.A. Lamb, 2001) 
and are basically classified into three subtypes: A, B and C. The principal 
differences between the three subgroups are based on the number of the segments 
present in the genome and thus on the antigenic features of their internal proteins, 
nucleoprotein and matrix. Influenza A and C viruses infect multiple species, while 
influenza B almost exclusively infects humans. Influenza A and B viruses are 
responsible of most of the cases of human disease and cause annual epidemics. 
They are antigenically distinct and do not exhibit cross-immunity or gene 
recombination. Influenza A viruses are essentially avian viruses that occasionally 
infect other species including humans. Avian infection is usually asymptomatic, 
and viruses replicate in the intestine of aquatic birds, creating that constitute a large 
reservoir of potential pandemic viruses.   
The eight, negative-sense, RNA segments of the influenza virus genome encode 11 
different proteins, of which 8 are packaged into the infectious, enveloped, virion. 
On the viral surface are the two main antigenic determinants of the virus, the spike 
glycoproteins: hemagglutinin (HA) and neuraminidase (NA). HA mediates viral 
entry into cells and has receptor binding and membrane fusion activity. NA 
mediates enzymatic cleavage of the viral receptor at late stages of infection, 
allowing for the release of progeny virions (A., 1957). A third integral membrane 
protein, M2, is a multi-functional, proton-selective, ion channel which has roles 
both in virus entry as well as in assembly and budding. Inside the viral envelope, 
the matrix protein (M1) provides structure to the virion and bridges interactions 
between the viral lipid membrane and the ribonucleoprotein (RNP) core. The RNP 
core is composed by the RNA polymerase complex proteins, PB1, PB2 and PA, 
and the nucleocapsid protein (NP) which mediates binding and packaging of the 
viral genome. During virus replication three other proteins are expressed that are 






functional protein with a major role in evasion of the host immune system. NS2 
(NEP) plays a crucial role in mediating the export of viral RNPs from the cell 
nucleus during replication (García-Sastre, 2011) (Figure 11).  
 
 
Influenza A viruses are grouped in subtyped based on sequence and antigenic of 
HA and NA. Up to now, 16 different HA and 9 NA have been described, most of 
which circulating in the avian reservoir. So far, cases of human infection resulting 
in annual epidemics have been attributed only to viruses carrying H1, H2,H3 and 
N1 or N2. When a virus strain with a new HA or NA subtype appears in the human 
population by genetic reassortment, it usually causes a pandemic because there is 
no preexisting immunity against the new virus. This was the case for example of 
the three pandemics that occurred during the last century (1918, 1957, and 1968) 
and also for the first pandemic of the 21st century, caused by the currently 
Figure 11_schematic structure of the Influenza A virus 
and genomic organization 







circulating A (H1N1) 2009 virus, which was generated by gene reassortment 
between a virus present in pigs of North America and a virus that circulates in the 
swine population of Euroasia. 
 
2.2. Virus replication cycle 
The exact mechanism for fusion of virus and cell is well established and a strong 
contribution to this type of knowledge has been given by crystallographic analysis.  
During the first steps of infection both HA and NA have crucial roles in mediating 
binding of the virus to the cell surface and release of the newly-formed viral 
particles, respectively.  
HA owns its name to its capacity of causing agglutination of red blood cells in vitro 
and this peculiar characteristic is conferred by the capability of the glycoprotein to 
bind sialic acid residues exposed on cell surface. In most viral strains it is present 
as native un-cleaved form, also called HA0 monomer. Each HA monomer presents 
a host receptor binding site that allows the virus to recognize terminal sialic acid 
moieties on glycolipids and glycoproteins on the surface of host cells. Since there 
are many copies of HA on each influenza virus particle, the attachment of influenza 
virus on the host cell surface is multivalent and has high avidity despite low 
affinity. The specificity and the affinity of the viral HA for its receptor is a crucial 
characteristic of host transmission. Cleavage of the HA0 protein is mediated by 
host-produced trypsin-like proteases and produces two subunits: HA1 and HA2. 
The mature form of HA on infective viral particles is a homotrimeric structure 
where each HA molecule consists of a globular ‘head’ domain, made up 
exclusively by HA1, and a fibrous stem composed by the entire HA2 and part of 
HA1 that is inserted into the viral membrane. The HA C-terminal cytoplasmic tail 







It is through the binding of HA to sialic acid residues that viral and host 
membranes fuse and thus the infective process starts by internalization of the virion 
inside the host cell through classical receptor mediated endocytosis in clathrin-
coated vesicles. During the endocytosis process, the M2 protein allows for the 
influx of protons leading to an acidic environment (Matlin KS, 1981). The 
acidification of endosomes is critical for the next step of the replication cycle of the 
virus for two reasons: 
6. It provokes a conformational change in the HA favoring  the fusion of the 
viral and cellular membranes and this allows the virus to enter the cell 
cytoplasm 
7. It promotes the uncoating of the virus and allows the RNPs to dissociate 
from the viral particle, such that they are released into the cytoplasm and 
transported to the cell nucleus.  
Figure 12_Entry and replication pathway of influenza virus 






Once in the nucleus of infected cells, the viralRNA-dependent RNA polymerase 
transcribes and replicates the negative sense vRNA. The positive RNA strand 
obtained is used as a template for the synthesis of new virion genome and for 
mRNA transcription and viral protein translation (Cros JF, 2003). All mRNA 
molecules are then transported back to the cytoplasm by the viral proteins NEP and 
M1 and once in the cytoplasm they are translated by the host cell machinery. The 
surface proteins HA, M2 and NA are synthesized in the endoplasmic reticulum 
(ER), glycosylated in the Golgi apparatus and finally transported to the cell 
membrane for virion assembly. The progeny virions assemble and bud at the 
plasma membrane (Figure 12).  
The new progeny of virions remain initially bound to outside membrane sialic acid 
residues because of their interactions with HA spikes until NA sialidase activity 
remove them from cellular and viral glycoconjugates. For its peculiar activity, NA 
has also a role in preventing the aggregation of the new virions as well as in 
mediating their release. Once released from host cells the new virions can infect 
nearby cells and spread the infection. 
 
2.3. Viral tropism and antigenic variation 
Influenza A viruses circulate in a wide variety of animals, most of which are only 
transiently infected. The largest variety of influenza A viruses circulate in birds. 
Besides birds, additional animal reservoirs of influenza A viruses are found in 
mammalian species such as swine and horses.  
The major determinants of the tropism of influenza viruses are the sialic acid 
molecoles because of their initial interaction with HA to start infection. Sialic acid 
residues are nine-carbon monosaccharides present in variable amounts on the 
surface of different cell types, usually bound to galactose through α2,3 or α2,6 
linkages. HA from different viruses show a preferential binding avidity for the type 






with α2,6 linkages, whereas avian viruses bind mostly to SA in an α2,3 
configuration (Ito T, 1998; Ito T, 2000; Ito T, 1997). The human tracheal epithelial 
tissue preferentially express SA with a2,6 linkages, whereas avian epithelial 
gastrointestinal tissue (where influenza viruses replicate in avian hosts) contain 
mainly SA in an a2,3 configuration. Of relevance, pig tracheal tissue has both kinds 
of SA linkages, and swine can thus be infected with viruses that recognize both 
types of receptors, hence, these animals have often been proposed as a mixing 
vessel for the generation of new strains from co-infections of avian and mammalian 
viruses.  
It is noteworthy that Influenza A viruses evolve constantly using different 
mechanisms. Three are the best known mechanisms able to generate further 
variability in influenza A viruses. The most important is the lack of proofreading 
activity of the viral RNA polymerase during replication of the influenza genomic 
RNA segments, which results in a high level of point mutations, phenomenon that 
is also known as antigenic drift. The permanent antigenic drift in the principal 
targets of the immunological response, the proteins HA and NA, is the cause of the 
constant need to review the viruses that are included in the yearly prepared 
vaccines. The antigenic drift that has occurred in influenza A viruses for thousands 
of years has led to the current diversity of HA and NA subtypes. The second 
mechanism, known as antigenic shift, relies in the segmented nature of viral 
genome. This peculiar characteristic permits the formation of new progeny  viruses 
with novel combination of segments when two or more different virus subtypes 
infect a single cell. This process is capable of introducing new proteins in 
circulating viral populations that can drastically change the biological properties 
of the virus. Antigenic shift is commonly associated with appearance of pandemic 
influenza viruses. A third mechanism associated with evolution of influenza A 
viruses is  recombination by template switching. This type of recombination may 






viralRNAsegments, and these nonhomologous recombination events could be 
































3.1. Neisseria meningitidis 
Neisseria meningitidis is a gram negative, encapsulated bacterium, which is 
generally a commensal that colonizes the mucosal epithelium of the nasopharynx 
of the human population. Colonizing strains can belong either to hypervirulent 
lineages which are generally associated with disease, or to carriage strains that 
provides a reservoir for meningococcal infection and can also contribute to 
establish host immunity (DS, 2009). For still unknown reasons, the carriage strains 
can invade the pharyngeal mucosal epithelium and, in the absence of bactericidal 
serum activity, disseminate into the bloodstream, causing septicaemia. In a subset 
of cases, bacteria can also cross the blood-brain barrier and infect the cerebrospinal 
fluid, causing meningitis. 
With the exception of sporadic case reports, all known disease-causing 
meningococcal strains are surrounded by a capsule made up by complex 
polysaccharides, which confers resistance to phagocytosis and complement-
mediated lysis. Even if the capsular polysaccharide (CPS) inhibits bacterial 
adhesion because it masks the action of meningococcal adhesins, it is known to be 
crucial for bacterial to survive in the blood.  
Based on the immunogenicity and chemical structure of the CPS, N. meningitidis 
(Nm) can be classified into at least 13 serogroups A, B, C, E-29, H, I, K, L, W-135, 
X, Y, Z, and 29E  (SE, 1953). Among them, only six serogroups (A, B, C, W-135, 
X, Y) have been associated with meninogococcal disease and are thus considered 
pathogenic. Further  classification into serosubtype, serotype and immunotype is 
based on class 1 outer  membrane proteins (PorA), class 2 or 3 (PorB) outer 
membrane proteins and  lipopoly[oligo]saccharide structure, respectively 









3.2. Colonization and carriage 
The first step known to establish carriage and invasive meningococcal disease is 
the colonization of the upper respiratory mucosal tract by Nm. The bacterium can 
be acquired through inhalation of respiratory droplets and secretions.  
This acquisition can be either asymptomatic, or (infrequently) give rise to a local 
inflammation, invasion of mucosal surfaces, access to the bloodstream and 
fulminant sepsis, or focal infections such as meningitis (Stephens DS, 2007). 
Meningococcal disease usually occurs 1–14 days after acquisition of the pathogen. 
Acquisition may also result in upper respiratory and pharyngeal meningococcal 
carriage. The duration of carriage can vary from days to months. The probability of 
meningococcal disease after the acquisition of Nm declines very sharply, such that 
invasive disease becomes unlikely 10–14 days after acquisition. 
 
3.3. Meningococcal adhesion and cell invasion 
The adhesion to the respiratory epithelium is essential for Nm survival, colonization 
and transmission, and is also a prerequisite for invasive meningococcal disease. 
Upon contact with human cells, the meningococci forms microcolonies and adheres 
using pili.  Nm has evolved numerous surface-exposed adhesive structures that 
facilitate interactions with human cells. Bacterial host-specificity resides in the 
structural specificity of the meningococcal ligands for human molecules, which can 
range from nutrients, to serum/secreted proteins and surface-located adhesion 
receptors. Mechanisms of meningococcal adhesion are multifactorial, dynamic and 
display temporal changes during the course of infection.  After the initial 
colonization, there is a loss or down-regulation of the capsule, which sterically 
masks the outer membrane proteins. This event is key to unmask adhesins that 
serve to mediate subsequent adhesion to the human epithelium.  Antigenic and 






important role, and the presence of multiple adhesins compensates for phase 
variation and may lead to an altered tissue tropism. Close adherence of 
meningococci to the host epithelial cells results in the appearance of cortical 
plaques and the recruitment of factors leading to the formation and extension of 
epithelial cell pseudopodia that engulf the bacteria (DS, 2009). This intracellular 
lifestyle can give the bacteria the opportunity to evade host immune response, 
finding more available nutrients, and eventually, to further cross the epithelium 
entering the blood stream (DS, 2009). Intracellular meningococci reside inside 
membranous vacuoles and are capable of translocating through basolateral 
epithelial tissues by transcytosis within 18-40 hours. Within the cells, 
meningococcus has to express again the capsule, which can prevent antibody and 
complement deposition (M., 1995), is anti-opsonic and anti-phagocytic and 
therefore aids survival in blood (M., 2009). Once in the bloodstream, meningococci 
may multiply rapidly to high numbers and eventually translocate across the blood-
brain barrier, proliferate in the central nervous system and cause meningitis. These 
later steps in invasion are still poorly understood. The ability to cause invasive 
disease is influenced by a multiplicity of environmental and microbial factors, as 
well as from the absence of host’s protective antibodies. 
 
3.4. Anti-meningococcal vaccines 
Several meningococcal vaccines are available against the distinct serogroups. 
Vaccines against meningococcal serogroups A and C have been developed and 
tested in clinical trials (Costantino P, 1992) (Anderson EL, 1994); (Fairley CK, 
1996). The first trials conducted in the United Kingdom with the meningococcus C 
conjugate showed a dramatic decline in the incidence of serogroup C disease in all 
age groups ( (Borrow R, 2000) (Miller E, 2001) with an efficacy of 97 and 92 per 






meningococcus are now available as monovalent (A or C) or as different tetravalent 
formulations (A, C, W-135 and Y). 
The most critical target for vaccination is meningococcus B (MenB), which is 
responsible for 32 percent of all cases of meningococcal disease in the United 
States and for 45–80 percent of the cases in Europe. Conventional biochemical and 
microbiological approaches have been of little help in the development of a vaccine 
able to induce broad protection against menB. A polysaccharide-based vaccine 
approach could not be used for group B meningococcus, since the principal 
component of its CPS that is a polymer of Æ(2-8)-linked N-acetylneuranimic acid., 
which is also abundantly expressed in human tissues. Alternative approaches to 
develop MenB vaccines have focused on the use of surface-exposed proteins 
contained in outer membrane preparations (outer membrane vesicles, OMVs). The 
first OMV vaccines were developed in Norway and Cuba and showed efficacy in 
humans ranging from 50 to 80 per cent (al, 1999). However, while each vaccine 
was shown to induce good protection against the homologous strain, both failed to 
induce protection against heterologous strains (Rosenstein NE, 2001). The major 
protective antigen in both these vaccines is PorA, the most abundant outer 
membrane protein, which is known to be highly variable across different isolates of 
serogroup B N. meningitidis. 
To overcome these limitations, a novel multicomponent recombinant protein-based 
vaccine, named 4CMenB or Bexsero®, has been recently developed by Novartis 
Vaccines and Diagnostics against group B meningococcal strains. Bexsero® is now 
approved in Europe and Australia.  
4CMenB is based on antigens identified through an innovative genetic approach 
known as ‘reverse vaccinology’ and combines OMVs from the New-Zealand 
epidemic strain (NZ98/254) with three major protein antigens: factor H-binding 
protein (fHbp), Neisserial Heparin-Binding Antigen (NHBA) and Neisserial 






fHpb (sub-variant 1.1) and NHBA (peptide 2), are present as fusion proteins to two 
minor antigens, GNA2091 and GNA1030, respectively. Another vaccine against 
serogroup B, developed by Pfizer, has been approved in America and contains two 
alleles of the recombinant fHbp. 
 
 
3.5. Factor H binding protein (fHbp) 
Factor H binding protein (fHbp or GNA1870) was the first discovered antigen 
effective in inducing bactericidal antibodies. It was identified by screening the 
genome of one of the most virulent strains: MC58. fHbp is known to bind 
specifically to human factor H (fH), an inhibitor of the alternative complement 
pathway. Since the evasion of the human complement system is key for Nm to 
cause the invasive disease, different studies have been addressed the role of  fHbp 
Figure 13_Schematic representation of the 4CMenB vaccine antigens on the 
surface of N. meningitides. The main antigens identified through reverse 







in host invasion and it has been shown that the its deletion results in increased 
susceptibility of most strains of Nm to killing in either serum or in whole blood.  
The three-dimensional (3D) solution structure of fHbp has been resolved by 










These studies revealed that the protein is composed of two domains connected by a 
short linker: an N-terminal domain of 8 beta-strands, forming a highly curved anti-
parallel beta-sheet, and a C-terminal domain that is a well-defined beta-barrel of 8 
anti-parallel beta strands (Figure 14). Although fHbp is known to have ~300 
sequence variants, multiple-sequence alignments show that the residues forming of 
the hydrophobic cores of both C- and N-terminal domain are well conserved 
predicting that the final 3D structure should be the same in all variants.  The fHbp 
proteins can be classified into three genetic and immunogenic variants: fHbp-1, 
fHbp-2 and fHbp-3, which are not cross-protective, and can be further divided into 
subvariants. Among each variant, fHbp sequences are conserved across different 
strains (92 to 100%), while between the 1-3 variants sequence conservation is low 
(63%). This diversity has an important impact on the immunological features of 
fHbp, since members of each variant induce a strong protective immune response 
against meningococcal strains carrying homologous alleles but not against strains 
expressing distantly related variants (Masignani V, 2003).   
Figure 14_Structure of fHbp. The 
currently known structure of the 
fHbp formed by two beta-barrel 
domains (one domain N-terminal 
and the other C-terminal) connected 
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Outline of the thesis  
 
B cells are crucial components of adaptive immune responses. The way by which B 
cells interface and sense the external ‘danger’ is through their BCR. The initial 
heterogeneity of B cells created by the random rearrangement of V(D)J gene 
segments enables recognizing a multitude of foreign antigens. In the course of 
human life this vast repertoire of antibody is continuously re-shaped in order to 
generate a pool of diversified MBCs and PBs with different antigen specificities.  
Different studies are underlying the importance of dissecting the BCR repertoire of 
different B cell subsets following vaccination to gain insights on the dynamics of 
the vaccine response and to predict vaccine safety. This approach could help in 
understanding the specificity, the frequency and also the class of memory cells 
required to mediate protection, as well as the individual variability in the breadth of 
the response. Moreover, this analysis could allow discriminating useless versus 
harming responses. An increased knowledge on B cells, and in particular on MBCs 
and PBs responding to a given vaccine antigen, could be key for designing more 
effective vaccines able to stimulate and guide the ‘right’ immune memory 
responses.   
Due to the relevance of these types of studies, the principal objective of my PhD 
thesis was to investigate and follow the response of both MBCs and PBs over time 
after vaccination by sequencing the variable part of the Ig genes of single cells 
(through single cell PCR. scPCR of paired VH and VL) and by profiling the 
antibody repertoire changes  
However, when I started my PhD there were different challenges in introducing 
this approach, mainly represented by the lack of tools to identify and isolate antigen 
specific MBCs and by the low efficiency of amplification of Ig scPCR obtained in 
MBCs compared to the pool of PBs. This has led my project to be divided in two 






manuscript  (Bardelli M, 2013) of an efficient approach developed to identify and 
sort HA specific MBCs as well as to amplify VH and VL genes by the use of 
scPCR. The robust technique developed in Novartis enabled to monitor quantitative 
and qualitative changes in the distribution of HA binding across different B cell 
subsets following vaccination, and to obtain enriched population of HA specific B 
cells for molecular cloning of paired VHVL Ig genes.  
The overall PCR efficiency we obtained in this first study by amplifying VH-VL 
genes from single memory B cells isolated from frozen hPBMCs ranged between 
17-35%, as described also in literature. To optimize the entire procedure of Ig-
scPCR, before moving to clinical samples, a new set of primers was designed for 
both RT and PCR steps. The application of this strategy to different B cell subsets 
enables to rescue the 60-80% of PCR products with an efficiency comparable in all 
cell types and improved in respect with the one obtained before.  
In the second part of my dissertation I will present the study that I have performed 
in the last year of my PhD aimed at broadly characterizing at phenotypic and 
molecular level the unexplored repertoire of circulating PBs and MBCs recruited in 
the interaction with Factor H Binding Protein (fHbp) antigen following 
Meningococcus B vaccination. PBs and fHbp-specific MBCs isolated ex vivo from 
human PBMC collected from two subjects before and at different time points after 
MenB vaccination have been characterized for their BCR repertoire. Moreover a 
comparison of the overall repertoire across the two individuals has been performed.  
The obtained results are described in a manuscript currently in preparation to be 









Ex vivo analysis of human memory B lymphocytes specific for A 
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Understanding the impact that human memory B-cells (MBC), primed by previous 
infections or vaccination, exert on neutralizing antibody responses against drifted 
influenza hemagglutinin (HA) is key to design best protective vaccines. A major 
obstacle to these studies is the lack of practical tools to analyze HA-specific MBCs 
in human PBMCs ex vivo. We report here an efficient method to identify MBCs 
carrying HA-specific BCR in frozen PBMC samples. By using 
fluorochrome-tagged recombinant HA baits, and vaccine antigens from 
mismatched influenza strains to block BCR-independent binding, we developed a 
protocol suitable for quantitative, functional and molecular analysis of single 
MBCs specific for HA from up to two different influenza strains in the same tube. 
This approach will permit to identify the naive and MBC precursors of 
plasmablasts and novel MBCs appearing in the blood following infection or 
vaccination, thus clarifying the actual contribution of pre-existing MBCs in 
antibody responses against novel influenza viruses.  Finally, this protocol can allow 
applying high throughput deep sequencing to analyze changes in the repertoire of 
HA
+
 B-cells in longitudinal samples from large cohorts of vaccinees and infected 
subjects with the ultimate goal of understanding the in vivo B-cell dynamics driving 
















The surface glycoprotein hemagglutinin (HA) plays a critical role in influenza virus 
infection, by anchoring viruses to surface sialic-acid residues on host cells and by 
mediating the subsequent fusion of viral and host cell membranes. Antibodies 
blocking these interactions are the only widely recognized correlate of protection 
from infection. Both influenza infection and vaccination prime durable immune 
memory in humans (1-3). Priming of immune memory by overt or subclinical 
influenza infection can occur early in life, thus most human immunizations occur in 
the context of pre-existing immunity. Influenza HA is highly susceptible to 
mutations and drifted variants capable to escape pre-existing neutralizing 
antibodies emerge continuously. For this reason influenza vaccines must be 
reformulated yearly. Whether, and to what extent, pre-existing memory B-cells 
(MBCs) play a role in preventing infection by new influenza variants is poorly 
understood (4-5).  
Convincing evidence showing that MBCs are recruited in early plasmablast 
responses to infection or vaccination has been collected by several groups (6-10), 
also during the 2009 pandemic (10-12). Most of this information has been obtained 
by applying the best state-of-the-art technologies for molecular cloning and 
expression of paired heavy and light variable immunoglobulin (IgVHVL) genes to 
arrays of single plasmablasts from multiple subjects (6,8-11). This has been 
possible because plasmablasts are identifiable by flow-cytometry based on the 
expression of well-defined surface markers but mostly because they appear in large 
numbers in the blood one week following infection or vaccination and therefore 
don’t need to be selected based on antigen specificity (6).  Applying similar 
approaches to analyze the repertoire of pre-existing antigen specific-MBCs would 
be key to verify their actual contribution in plasmablast responses to drifted HA 
antigens, as well as in antigen-driven germinal center reactions that ultimately 






antibodies of refined specificities.  A major obstacle to move in this direction is the 
lack of practical markers to identify rare antigen-specific MBCs within the bulk of 
MBCs present in ex vivo human PBMCs. Successful attempts to analyze and sort 
by flow-cytometry mouse B-cells binding to fluorochrome-labeled soluble HA 
molecules have been reported several years ago (13). Unfortunately, applying 
similar approaches to the analysis of PBMC samples from human influenza 
patients or vaccinees has proved challenging so far (14-15), due to non-specific 
binding of HA to the surface of all human leukocytes.  
We explored different approaches to sort HA-specific MBCs and found that an 
efficient method to prevent non specific binding of influenza HA is pre-saturation 
of PBMCs with influenza mono-bulk vaccine antigens (that is, monovalent bulk 
vaccine antigen before final formulation into multivalent mixtures, filling, and 
finishing) from a strain mismatched to the one used as fluorescent bait. By using 
influenza A and B mono-bulks as saturating reagents, we developed a staining 
protocol suitable for direct flow-cytometric analysis of B-cells specific for HA 
from up to two different mismatched influenza strains in the same human PBMCs 
sample. This technique can be applied to monitor quantitative and qualitative 
changes in the distribution of HA binding across different B-cell subsets following 
vaccination, and to obtain enriched population of HA-specific B-cells for molecular 
cloning of paired VHVL-Ig genes. This protocol provides a unique tool to compare 
HA-specific B-cell repertoires across cohorts of subjects with different histories of 
influenza exposure and to obtain information suitable for the development of novel 












Detection of BCR-dependent binding to soluble influenza recombinant HA 
baits  
To identify B-cells engaged into BCR-specific interactions with influenza HA we 
first tried to stain PBMCs with monoclonal antibodies against the B-cell marker 
CD20 and the B-cell memory marker CD27 mixed with a recombinant H1 bait 
(rH1), or with human serum albumin (HSA), both conjugated with the Alexa-488 
fluorochrome (A488). When stained with rHA, PBMCs gated on live singlets 
(Fig.1A) showed a high and diffuse fluorescent signal on both B and non B-cells, 
while staining with HSA-A488 only gave background signal (Fig.1B).  
Human influenza HA is known to bind 2,6 sialic-acid residues (16), which are 
expressed on human leukocytes and are particularly abundant on B lymphocytes 
(17-18). We tried to block this interaction by adding a 100-fold molar excess of 
soluble sialopentasaccharides containing 2,6-linkage to the staining solution. 
While this prevented indiscriminate binding of rH1 to most leucocytes, it was not 
sufficient to block rH1 binding to all B lymphocytes (Fig.1B). Little, or no 
improvement was observed in experiments in which we pre-incubated PBMCs with 
compounds known to bind to α2,6-sialic-acid residues with high affinity, such as  
α-fetuin, or the Sambucus nigra lectin (19) (data not shown).  
We then evaluated the possibility of removing sialic-acid residues from PBMC 
surfaces, or covering them with vaccine subunit mono-bulk antigens, purified from 
an influenza A subtype mismatched to that of the fluorescent HA bait.  Equal 
numbers of PBMCs from the same donor were incubated for 30 minutes either at 
37°C with Clostridium perfringens type VIII neuraminidase (NA), or on ice with a 
vaccine mono-bulk H3N2 antigens (from A/Panama/2007/1999). Both PBMCs 
samples were then stained with anti-CD20, anti-CD27 and an A488-tagged rH1 
bait. Following either treatment the frequency of H1-binding B-cells was greatly 






H3N2-pre-saturated sample) and most of the H1
+
 B-cells expressed the CD27 
B-cell memory marker (Fig. 1C).   
Because these staining patterns were consistent with that expected for MBCs 
binding to H1 through BCR-specific interactions, we sorted H1
+
 B-cells from both 
samples to verify their specificity by ELISPOT. To induce resting B-cells to 
differentiate into antibody secreting cells (ASC), the two sorted H1
+
 B-cell 
populations were cultured with CpG and IL-2, in the presence of autologous CD20-
negative (CD20
neg
) feeder cells, in a ratio of 1:200 to achieve a cell density of at 
least 10
6
 cell/ml. To exclude interference from ex vivo activated H1-specific 
plasmablasts putatively included among CD20
neg
 cells, an aliquot of CD20
neg
 cells 
was also mixed with H1-negative (H1
neg
) B cells sorted from the NA-treated 
sample and placed in culture with CpG and IL-2. Unsorted PBMCs were also 
activated in the same way to assess the starting frequency of H1
+
 ASC precursors. 
The results from these experiments showed that the two H1
+
 B-cell populations 
generated comparable numbers of ASC producing H1-specific IgG and at enriched 
frequencies as compared to unsorted PBMCs (Fig. 1D). The frequency of ASC 
producing H1-specific IgG detectable in cultures of CD20
neg
 cells mixed with H1
neg
 
B cells was instead greatly reduced as compared to unsorted PBMC, showing that 
the contribution from H1-specific IgG ASC eventually generated from ex vivo 
activated CD20
neg
 plasmablasts was negligible. However, 95% of total IgG 
producing ASC generated from H1
+ 
B-cells sorted from H3N2-pretreated PBMCs 
produced H1-specific antibodies; conversely, only 19% of IgG-ASC generated 
from H1
+
B-cells sorted following neuraminidase treatment were H1-specific (Fig. 
1D).  
These results were confirmed in 2 other experiments in which the proportion of 
H1-specific IgG-ASC generated from H1
+
 B-cells sorted from H3N2-, or 







Based on these results, we concluded that blocking BCR-independent binding sites 
with mismatched influenza subunit antigens increases the specificity of identifying 
H1
+




Figure 1. Blockade of sialic-acid binding sites reveals BcR-dependent binding to influenza HA. 
A-B. Diffuse binding of rH1 to untreated human PBMC. Thawed PBMCs from an anonymous 
blood donor were first stained with Live/Dead then with an anti-CD20 mAb mixed with 
Alexa488-conjugated human serum albumin (PBS/HSA), or Alexa488-conjugated rH1 from the 
A/California/07/2009 strain (PBS/rH1), or a solution of sialopentasaccarides containing the 
Alexa488-conjugated rH1 (-2,6-SPS/H1Cal). The strategy for gating on single live lymphocytes is 




 cells is shown in B. C. Blockade 
of sialic-acid binding sites reveals putative BcR-specifc binding of rH1. PBMCs from a single donor 
were split in 8 tubes (10
7
PBMC/each), 4 tubes were incubated with H3N2 mono-bulk subunit 
vaccine antigens from the A/Panama/2007/1999 strain (left dot plots), and 4 tubes with 
neuraminidase (right dot plots). Then the PBMCs were incubated with anti-CD20 and anti-CD27 
mAbs and A488-HSA (upper plots), or A488-rH1 (lower plots). Shown is the distribution of rH1 
binding on memory (CD27
+
) and naïve (CD27
-
) B cells identified in the CD20
+
 gate. D. Specificity 
of rH1 binding. H1
+
 B-cells sorted from H3N2- (n=1372) or neuraminidase- (Neur) (n=2233) 
treated PBMCs were mixed with sorted autologous CD20
-
 cells in the ratio of 1:200 and activated in 
vitro with CpG and IL-2 for 5 days. As controls, cultures of unsorted PBMCs, as well as of 
autologous CD20
neg
 cells mixed with H1-negative (H1
neg






PBMCs (n=30,000) in the ratio of 1:10 were run for 5 days in the presence of CpG and IL-2. After 5 
days, cells from each culture were harvested, washed, counted and assayed by ELISPOT to 
enumerate cells secreting IgG and H1N1-specific IgG. To facilitate comparisons between different 
cell cultures and across experiments depicted in different figures, the results are expressed as 
numbers of antibody secreting cells (ASC) normalized to 10
6
 cultured cells assayed by ELISPOT.  
 
Sensitivity and robustness of flow-cytometric analysis of HA-specific B-cell 
frequencies in ex vivo PBMCs  
To obtain insights into the sensitivity and robustness of this approach, the 
frequencies of resting HA-specific IgG MBCs were measured both by 
flow-cytometry and by B-cell ELISPOT in PBMCs from 4 donors and in three 
different experimental sessions. For flow-cytometric analysis we used rH1 from the 
A/Solomon Island/03/2006 strain. The specificity of the H1
+
 B-cell subset was 
verified by ELISPOT following activation of sorted H1
+
 B-cells with CpG, IL-2 
and autologous CD20
neg
 B cells for 5 days (Fig. 2 A and B) using PBMC from a 
fifth donor. The capture antigen used in the ELISPOT assay was the H1N1 
mono-bulk subunit from the same vaccine strain. To assess the frequency of H1
+
 B 
cells expressing the IgG isotype among total H1
+
 B cells detected in each of the 
four donors, an anti-IgG mAb was added to the staining protocol (figure 2 C).  
The results of these comparisons showed that the frequencies of H1-specific IgG 
MBCs detected by flow-cytometry and by ELISPOT were linearly correlated and 
that the correlation was statistically significant (Fig. 2D; R
2
 = 0.73; p = 0.0005). In 
addition, the variability of H1-specific IgG MBC frequencies measured by either 
method was comparable (Fig. 2E).  
These results support the notion that our staining protocol can be applied for 
measuring HA
+ 
MBC frequencies in ex vivo PBMCs samples, with comparable 
















 MBCs frequencies measured by flow-cytometry and by ELISPOT 
correlated linearly  
A-B. Specificity of the staining with the rH1 bait from A/Solomon Island/3/06. PBMCs (1.6x10
8
) 
from anonymous blood donors were stained with Live/Dead, incubated with an H3N2 mono-bulk 
vaccine subunit (from A/Panama/2007/1999), and then stained with Alexa647-conjugated HSA 
(6x10
7
), or Alexa647-conjugated rH1 (1x10
8
), and with an antiCD20 mAb. A. Binding pattern of 
HSA (A647-HSA; left panel) and of rH1 (A647-rH1; right panel) in the CD20
+
 B-cell gates. B. H1
+
 
B-cells identified in A were sorted (n=8215), mixed with autologous CD20
neg
 cells in the ratio of 
1:50 and activated with CpG and IL-2 for 5 days in vitro. Unsorted PBMC and CD20
neg
 cells were 
also cultured in the same manner as controls. After 5 days, equal numbers of cultured cells were 
harvested and assayed by ELISPOT for numbers of cells secreting IgG and IgG specific for H1N1 
(from A/Solomon Island/3/06). Results are expressed as number of antibody secreting cells (ASC) 
normalized to 10
6
 cultured cells assayed by ELISPOT. Nd indicates undetectable ASC. C. 
Distribution of IgG
+






 B cells expressing or not the CD27 B cell 
memory marker; shown is one representative subject. D. Replicates of frozen PBMCs from 4 
anonymous blood donors were assayed by conventional ELISPOT, or incubated with an H3N2 
mono-bulk vaccine subunit and stained with rH1, and anti-CD20 plus anti-human IgG antibodies. 




 B-cell frequencies measured by flow-cytometry 
(y-axis) and by ELISPOT (x-axis) across three different experimental sessions. Shown are: the 
regression line with the related 95% confidence interval (gray areas), slope, intercepts, R
2
 and 
p-value. D. Variability plot showing mean standard deviations of the measurements done by 







Simultaneous identification of B-cells specific for HA from A and B influenza 
strains in ex vivo PBMCs  
Next we assessed whether this approach was suitable to identify B-cells specific for 
HA from different influenza A subtypes, or from a type B influenza strain. PBMCs 
from two anonymous blood donors were pre-incubated with mono-bulk antigens 
from an influenza B vaccine strain and then stained with rHA from either A/H1N1 
or A/H3N2 subtypes. Alternatively, PBMCs from a third donor were first 
pre-incubated with mono-bulk antigens from an influenza A/H3N2 subtype and 
then stained with B/rHA.  B-cells putatively engaged in BCR-dependent binding to 
the rHA antigens were identified in each sample. Since applying a stringent gate 
only on bright H3+ or B/HA+ cells (rectangles in left panels of Fig. 3A) would 
have not permitted to obtain sufficient numbers of cells for ELISPOT tests, the 
sorting gates were set with lower stringency (dashed lines in left panels of Fig. 3A). 
In each sample HA
+









) B cells in comparable manner to HA
neg
 B cells 
(Fig. 3B).  All the HA
+
 B-cell populations were sorted and activated in vitro with 
CpG, IL-2 and autologous CD20
neg
 B cells, to verify the specificity of the staining 
by ELISPOT. Unsorted PBMC, as well as autologous CD20
neg
 B cells mixed with 
HA
neg
 B cells were also placed in culture as controls and activated in the same 
manner. After 5 days in culture, all the sorted HA
+
 B-cell populations were 
enriched in B-cells expressing IgG specific for the HA baits. Fig. 3C depicts the 
results from a representative experiment where the fold enrichments in IgG-ASC 
specific for H3 (from A/Brisbane/10/07), H1 (from A/California/07/09) or B/HA 
(from B/Brisbane/60/08) were 210x, 29x, and 180x, respectively. No IgG-ASC 
specific for HA were detected in cultures of CD20
neg
 B cells and HA
neg
 B cells 
(Fig. 3 C). In this experiment the highest frequency of ASC producing HA-specific 
IgG HA was observed in the cultures of H1
+
 B-cells (68% of total IgG producing 






panels). Comparable results were obtained with PBMCs from other two donors (not 
shown).  
We then explored the possibility of combining two baits from different influenza 
strains to analyze B lymphocytes binding to either HA antigen in the same PBMC 
sample. Fig. 4 depicts the results obtained with PBMC from a single donor that 
were split into two tubes and either pre-incubated with a B/HA vaccine mono-bulk 
and stained with equal amounts of A647-rH3 and A488-rH1 (Fig. 4A), or 
pre-incubated with an A/H3N2 vaccine mono-bulk and stained with the A488-rH1 
paired with an A647-B/rHA (Fig. 4B). H1
+
 B-cells were detected at comparable 
frequencies, irrespective of the type of the mono-bulk used as blocking agent (0.4 
and 0.3 % of total CD20
+





B-cells. The results obtained from the analysis of PBMCs from 16 different donors 





subsets were largely non-overlapping (Fig. 4C). B-cells putatively cross-reactive 
with H1 and H3 were detected in 13 out of 16 subjects at frequencies 10 to 
100-fold lower than those of B lymphocytes binding only to the H1 or the H3 bait 
(Fig. 4C, insert).  
Overall, these results show that, by designing appropriate staining protocols, 
flow-cytometry can offer the unique opportunity to identify and sort single B-cells 
















Fig 3. Identification of B lymphocytes specific for HA from A and B influenza strains in ex 
vivo PBMCs samples  
PBMCs from different anonymous blood donors were pre-incubated with vaccine mono-bulk 
subunits from the B/Brisbane/60/2008 (B/HA pretreatment), or the H3N2 A/Panama/2007/1999 
strain (A/HA pretreatment) and then stained HSA, rH3 (from A/Brisbane/10/2007), rH1 (from 
A/California/07/2009), or B/HA (from B/Brisbane/60/2008), as indicated. A. Staining pattern 
observed on CD20
+
 cells in PBMC stained with the different rHA bait. The rectangular gates 
identify brilliant HA+ B-cells; the dotted vertical lines mark the gates used to sort HA
+
 B-cells for 




 B cells 







B-cells identified in A were sorted, mixed with autologous CD20
neg
 cells (in the ratio of 1:20, 1:100 





B cells were also cultured in the same manner, as controls. After 5 days cultured 
cells were harvested and assayed by ELISPOT for the number of cells secreting IgG and IgG 
specific for mono-bulk subunits from the vaccine strain homologous to the sorting bait. Results are 
expressed as numbers of antibody secreting cells (ASC) normalized to 10
6
 cultured cells assayed by 












Figure 4. Simultaneous identification of B lymphocytes specific for HA from different 
influenza strains in ex vivo PBMCs samples  
A. PBMCs from an anonymous blood donor were pre-incubated with subunits from either 
B/Brisbane/60/2008 or A/Panama/2007/1999 (H3N2), and then stained with anti-CD20 mAb, HSA 
conjugated with A488 and A647, with A647-rH3 (from A/Brisbane/10/2007) and A488-rH1 (from 
A/California/07/09), or with A647-rB/HA (from B/Brisbane/60/2008) and A488-rH1 (from 
A/California/07/09). The staining patterns observed in the CD20+ B-cell gate are shown. B. PBMCs 
from 16 anonymous blood donors were pre-saturated with B/Brisbane/60/2008 and then stained 
with anti-CD20 mAb, A647-rH3 (from A/Brisbane/10/2007) and A488-rH1 (from 
A/California/07/09). The scatter plot depicts paired values of H1
+
 (y-axis) and H3
+
 (x-axis) B-cells. 








 B-cells in the same 16 donors. 












Molecular cloning of HA
+
 B-lymphocytes 
Next, we assessed whether B-cells sorted based on HA binding are suitable for 
molecular cloning of IgVHVL genes. To this aim, PBMCs from four blood donors 
were first incubated with B/HA vaccine antigens and then with an anti-CD20 mAb 
and the rH1-A647 and rH3-488 baits. B-cells that bound to H1 (H1
+
 B-cells) and 




 B-cells) were sorted from 
two donors; from the other two donors we sorted H1
+
 B-cells and few cells binding 
to H3 (H3
+
 B-cells).  
To clone paired VHVL sequences we applied the single cell RT-PCR Ig-gene 
amplification protocol previously described (20-21). The efficiency of molecular 
cloning ranged between 17% and 38%. Since these cells were obtained from frozen 
PBMCs, we couldn’t directly compare these values to the 40-60% cloning 
efficiency obtained using freshly isolated PBMCs by the authors of the RT-nested 
PCR protocol (21). Reassuringly, however, pairs of VHVL sequences were obtained 




B-cell subsets sorted from the 
same donor (38% for H1
+











 B-cells from donor #4), suggesting that BCR-binding by 
rHA had no substantial impact on cell viability and mRNA degradation. 
All arrays of sorted cells comprised single clones; only in one donor we found two 
H1
+
 clones that expressed identical VHVL rearrangement with few different 
mutations (clones 53 and 87 from donor #2, Supplementary Table 1).  
The distribution of VH and VL gene family use was similar across the different 
arrays of sorted B-cells, as well as across the four donors (Fig. 5). Use of VH3 
segments was dominant in HA
+
 B-cells from three out of four donors; the second 
most represented family being VH4 and the remaining VH1 or VH5 (Fig. 5A). The 
DH3 family was most frequently used in HA
+
 B-cells from 3 donors, followed by 
DH2 and DH6 and at lower frequency by DH1, DH4 and DH5 (Fig. 5B). The most 






followed by JH5, JH3, JH2 and JH1 families (Fig. 5C).  Similarly, genes from the 
VK1 and VK3 families were most frequently expressed in all arrays of clones and 
most of them were rearranged with JK1 or JK4 genes, less frequently with JK2, JK3 
and JK5 genes (Fig. 5D and 5E). 







 clones from the two donors analyzed in this manner (Fig. 5). 






 B-cells showed that, 
in donor #4, these two B-cells subsets carried remarkable differences. As shown in 
Fig. 5F, VL sequences cloned from H1
+
 B-cells of subject #4 displayed 
significantly higher numbers of mutations leading to dissimilar amino acid 




 B-cells (p<0.036, one-tail Wilcoxon 
non-parametric test). Conversely, no differences were found when comparing 
mutations leading to similar amino acid substitutions in VL regions (Fig. 5H), 






 B-cells could have evolved under different 
antigen-driven selection pressures. No differences were ever found between 
numbers of mutations leading to either dissimilar, or similar, amino acid 
substitutions in the VH regions (Figs. 5 G and I). 
In conclusion, these results show that the protocol developed to identify single 
HA-specific B-cells by flow-cytometry is applicable for molecular cloning and 



























Figure 5. Molecular cloning of HA
+
 B lymphocytes 











 B-cells were sorted to perform molecular cloning and analysis of their paired 
VHVL Ig regions as described in Material and Methods section. A-E. Distribution of VH (A), DH (B), 
JH (C), Vk (D) and Jk (E) gene use across arrays of B-cells sorted from each donor (16 and 18 HA
+
 
clones from donors #1 and #2; 35 HA
+
 and 20 HA
neg
 clones from donor 3; 16 HA
+
 and 16 HA
neg
 






 B-cells from donors #3 
and #4, which cause dissimilar (F, H) or similar (G, I) amino acid substitutions in VH (G,I) and VL 
(F,H). NS and ** indicate not significant, or significant (p<0.036) difference between mean 









Analysis of qualitative and quantitative changes in HA+ B-cells induced by 
vaccination  
Finally we asked whether the method we developed could be applied to analyze 
quantitative and phenotypic changes in the pool of HA-binding B cells induced by 
influenza vaccination.  For this analysis we took advantage of the availability of 
PBMCs samples collected at baseline and at days 21 and 43 after vaccination from 
four volunteers enrolled in a study performed during the 2007/2008 northern 
hemisphere influenza season (E.F. et al. manuscript in preparation). These samples 
were incubated first with H3N2 mono-bulk antigens and then with an A647-rH1
+ 
(from the 2007/2008 H1N1 vaccine strain A/Solomon Island/03/2006) and 
monoclonal antibodies against the CD20 B-cell marker, the CD27 memory marker 
and IgG.    
At baseline, all subjects had measurable numbers of H1
+
 B-cells (Figs. 6A and 6B). 
Following vaccination, the frequencies of circulating H1
+
 MBCs cells increased 
from 1.5 to 8 fold over baseline values (Figs. 6A and 6B). In three out of four 
subjects the expansion of H1
+
 B-cell paralleled the rise of circulating antibodies 
capable of blocking hemagglutination. A delayed expansion of H1
+
 B-cells, 
measurable at day 43 was observed in subject c, which was the only subject with 
high antibodies against the H1N1 strain at baseline (Fig. 6B).  
It is important to note that vaccination also induced remarkable changes in the 
distribution of H1
+
 B-cells across different MBCs subsets. At baseline, the majority 
of H1
+
 B-cells distributed across mature memory (CD27
+
) and immature 




) B-cells (Figs. 6A and 6C). By day 21, 
the proportion of H1
+
 B-cells expressing both the CD27 memory marker and an 
IgG-switched immunoglobulin receptor increased in all subjects to values that were 
2 to 4-fold higher than those observed at baseline (Fig. 6C, upper right panel). The 
proportion of H1
+















Comparable changes were never observed in the population of H1
neg 
B-cells (Fig. 













Figure 6. Vaccination induced changes in the pool of H1+ B-cells 
PBMCs samples collected before (day 0) and at 3 and 6 weeks after vaccination from four seasonal 
influenza vaccinees, were pre-incubated with H3N2 subunit (from A/Panama/2007/1999) and then 
stained with rH1 A/Solomon Island/3/06) and mAbs anti-CD20, anti-CD27 and anti-human IgG. A. 
Dot plots gated on CD20
+
 B-cells showing the distribution of H1
+
 (middle panels) and H1
neg
 
(bottom panels) B-cells from donor #a across: the mature memory (CD27
+
) and putatively naive 
(CD27
neg


















 B-cells in 4 vaccinees before and at 3 and 6 weeks after seasonal vaccination 
are overlaid with paired titers of antibodies inhibiting virus-induced hemmaglutination measured in 
their blood. The frequencies of H1
+









 B-cells across same subsets 








Our findings demonstrate that B-cells carrying immunglobulin receptors specific 
for type A or B influenza HA can be identified in ex vivo PBMCs by using 
fluorochrome-tagged rHA as antigenic baits and unlabeled mismatched mono-bulk 
vaccine subunit antigens to block BCR-independent binding. Circulating HA
+
 B 
cells identified in this manner in samples collected before and after vaccination can 
be further characterized for relative frequency and phenotype, as well as being 
sorted for further in depth analysis.  
As antigenic bait, we used different recombinant full-length HA molecules, 
produced by Protein Sciences in the baculovirus-insect cell expression system. We 
opted for using rHA, instead of the influenza vaccine mono-bulk subunit 
preparations as bait for several reasons. First, the data available show that these 
soluble rHA preparations form trimers and higher order of structures, which retain 
hemagglutination activity and the expected antigenic properties of HAs (22). In 
addition, rHA preparations do not contain other influenza proteins, while 
mono-bulk vaccine subunits contain HA and some NA. Finally, these rHA are 
commercially available and can be used by most laboratories.  
There were two main obstacles to identifying, with high specificity, HA
+
 MBC 
circulating in human blood. 
First, when added directly to untreated PBMCs, the rHA baits bind to all human 
blood leucocytes. This result is in apparent conflict with previous findings from the 
Baumgarth’s lab supporting the use of flow-cytometry to analyze influenza HA 
specific B-cells (13). Using lymph node cells from mice immunized with the 
influenza PR8 virus and soluble PR8 HA as bait, they did not observe 
BCR-independent binding and succeeded in obtaining an enriched population of 
HA-specific B-cells (13). Such conflicting data can be reconciled by recent results 
showing that α2,6-N-acetyl sialic-acid residues, known to interact with high 






lymphocytes, independently of their activation status, either as intrinsic component 
surface-expressed glycoproteins, or bound to the lectin domain of B-cell-restricted 
CD22 inhibitory receptors (23). Conversely, most mouse B-cells express low levels 
of α2,6-N-acetyl sialic-acids on their surfaces, which transiently increase only in 
activated B-cells engaged in germinal center reactions (23).  Intriguingly, 
Baumgarth’s group reported that close to 90% of the HA
+
 B-cells identified in PR8 
immunized mice expressed surface markers characteristic of germinal center 
B-cells (13). 
In line with the hypothesis that multimeric interactions between rHA and 
CD22-linked α2,6- N-acetyl sialic-acids could be responsible of the diffuse binding 
of HA to human B-cells, the addition of short α2,6-sialylated pentasaccharides to 
the staining solution displaced rH1 from most human leukocytes but not from 
B-cells. Conversely, rH1 binding to human B lymphocytes was blocked when 
PBMCs were stained following a pre-incubation step with either C. perfringens 
NA, which cleaves α-2,3- α-2,6- and α-2,8-linked sialic-acids, or with H3N2 
human influenza mono-bulk antigens, which are known for preferential binding to 
α-2,6-sialic-acids. Of note, H1
+
 B-cells isolated from NA-treated PBMCs still 
contained a large number of cells producing IgG of unknown specificity. Because 
NA is less than 50% active at the pH and temperature conditions that preserve cell 
viability, the inefficiency of preventing non-specific HA binding by NA treatment 
was anticipated. In contrast, up to 95% of H1
+
 B-cells sorted from H3N2-preated 
PBMCs were confirmed as HA-specific by ELISPOT, supporting the use of this 
approach to prevent BCR-non-specific binding of fluorochrome-labeled rHA 
antigens. 
The second obstacle to specific sorting of MBCs with HA baits was that the 
specificity of the HA
+
 B-cell population was influenced by the stringency of the 
gates applied in the analysis. Because human beings are exposed to a multiplicity 






impossible. The use of autologous proteins, like HSA, is helpful to set the lowest 
gate for BCR-independent recognition. However, the use of such controls is clearly 
insufficient when dealing with pathogen receptor antigens, like HA, capable of 
multimeric interactions with their ligands.  In our experience, the mean 
fluorescence intensity of HSA-stained B-cells is often substantially lower than that 
of bona fide HA
-
 B-cells stained with labeled rHA. Thus, to identify HA
+
 B-cells 
with great specificity we set the gate on brilliant HA
+





 B-cell frequencies in replicates of PBMC samples by 
this staining approach provided a series of values linearly correlated with those 
obtained by ELISPOT assays, and with similar range of variability across different 
experimental sessions. Clearly, a robust standardization of the gating strategy 
would require parallel flow cytometric and ELISPOT analyses of large number of 
samples across different laboratories. It is encouraging, however, that  the results 
obtained by analyzing PBMC samples from influenza vaccinees confirmed the 
adequacy of our gating approach to monitor quantitative and qualitative changes in 
HA-specific B-cell subsets induced by vaccination.  
Quantitative analysis of MBCs before and after infection or vaccination has been so 
far performed by B-cell ELISPOT, or limiting dilution assays (24, 25). These 
assays proved useful at gaining knowledge of the kinetic and the magnitude of 
MBC responses to influenza strains that did or did not circulate in the human 
population (3, 12, 24, 25). The major limitation of these assays is that they are not 
suitable for functional and molecular analysis of the antigen-specific repertoire at 
the single cell level ex vivo.  
We showed here that by combining rHA baits and monoclonal antibodies against 
surface B-cell markers our method is also suitable to analyze changes in the 
distribution of HA
+
 B-cells across MBCs subsets at different maturation stages (26) 
including in subjects who eventually did not experience a substantial increase in 
total number of HA
+








 B cells that expressed (or not) an IgG-switched BcR. A most in depth 
investigation of HA
+
 B cells expressing IgM or IgA receptors is clearly feasible by 
adding appropriate mAbs in the staining, as shown in supplementary figure 1. 
Overall, our observations provide strong support to the feasibility of standardizing 
flow-cytometry-based assays for monitoring directly in PBMC samples ex vivo 
quantitative and phenotypic changes induced in the repertoire of HA
+
 B-cells by 
influenza infection or vaccination. Moreover, the staining approach presented here 
can be used to sort arrays of single B-cells with different HA-binding specificities 
and to perform molecular cloning and in depth analysis of the VHVLIg repertoires, 
as it is currently done with short-lived plasmablasts circulating early after antigenic 
challenge.  
The possibility of combining two different HA baits in the same tube offers the 
opportunity of identifying rare circulating MBCs that cross-react between multiple 




 B-cells identified in some 
of our samples was not feasible because the informed consents signed by the 
anonymous blood donors did not include producing monoclonal antibodies from 




 B-cells in these samples was too low 
to apply an ELISPOT assay to verify their specificity. Nevertheless the results 
obtained by flow-cytometric analysis showed that the B-cells binding to A/H1 
segregated completely from those binding the B/HA bait, consistent with the low 
amino acid sequence homology between these HA molecules and the absence of 
serological cross-reactivity between type A and B influenza strains (27-28). 
Conversely, and in line with recent findings reported by multiple groups who used 
most complex B-cell cloning procedures (15, 29), in several PBMC samples we 
identified extremely low frequencies of B-cells putatively cross-reactive to group 1 
(H1) and 2 (H3) A influenza strains.  
A major limitation of our approach is that MCBs that cross-react between the 






between type A H1 and H3 and B HA molecules as those recently discovered (14) 
would not be present in the sorted arrays of brightly stained MBCs unless they have 
extremely higher binding affinity to the fluorochrome-tagged HA baits as 
compared to the HA subunit used to block non specific binding.   
Because human beings are exposed to annually changing antigenic variants of 
influenza HA, a deeper understanding of the protective potential of pre-existing 
MBCs repertoires is key to develop new and broadly protective vaccines. The 
approach reported here for direct analysis of HA-specific MBCs in ex vivo PBMC 
complements available methods to identify single plasmablasts, making possible to 
analyze all HA-specific B cell subsets circulating in the blood before and after 
vaccination. This will permit to verify the actual contribution of pre-existing MBCs 
in the generation of early plasmablasts and MBC expressing refined antibody 
specificities after infection or vaccination against novel (seasonal or pandemic) 
influenza viruses.  With this complete set of tools longitudinal analyses of 
IgVHVLIg phenotypically characterized repertoires of plasmablasts and HA
+
 MBCs 
from defined cohorts of subjects by deep sequencing will become possible, 
therefore allowing more rapid investigation of the in vivo B-cells dynamics driving 
the evolution of broadly cross-protective antibody responses against drifted 
influenza viruses. Greater understanding of these dynamics can aid the design of 














Materials and Methods 
Human Blood samples and Ethics Statement  
Leukopacs from anonymous healthy blood bank donors were collected during 
2010-2011 season after written informed consent was provided and ethical 
approval granted by the Institutional Review Board of the Empoli City Hospital, 
the Comitato Etico Locale Azienda 11 Empoli. The history of influenza infection 
or vaccination of blood bank donors was unknown. Ethical approval for collecting 
blood and performing B-cell analyses from volunteers, enrolled across 2008 and 
2009, in a Novartis’ sponsored clinical study with trivalent seasonal influenza 
vaccine given with or without avian H5N1 vaccine formulated with MF59 adjuvant 
(ClinicalTrials.gov Identifier: NCT00620815), was granted by the Ethical 
Committee of the medical faculty of Ludwig-Maximilians-University Munich. All 
clinical investigations have been conducted according to the principles expressed in 
the Declaration of Helsinki. The results of this clinical study will be the subject of a 
forthcoming paper (Fragapane E. et al. unpublished data). PBMCs were isolated by 
conventional centrifugation over a Ficoll gradient, frozen and stored in liquid 
nitrogen as previously described (12). All subjects provided written informed 
consent. The informed consents did not include permission for producing 
monoclonal antibodies from donors’ blood cells. 
Conjugation of HA with fluorochromes 
Recombinant HA (Protein Science) and HSA (Sigma-Aldrich) molecules were 
chemically labeled with Alexa Fluor 488 or Alexa Fluor 647 carboxylic acid 
succinimidyl ester (Molecular Probes, Invitrogen) following the manufacturer’s 
instructions. Each protein antigen was incubated with the dye at a molar ratio of 
1:10 for 1 hour at room temperature and then loaded into a Zeba desalting spin 
column (Thermo Scientific) to remove unbound dye. The degree of labeling was 
determined following the manufacturer’s instructions, by measuring the absorbance 






spectrophotometry. Protein concentrations were calculated by the BCA Protein 
Assay (Pierce, Thermo Scientific); the protein integrity was analyzed by 
SDS-PAGE.  
Flow-cytometry 
Frozen PBMCs were thawed at 37°C in PBS containing 2.5mM EDTA and 20 
µg/mL DNAse (Sigma Aldrich). Samples were stained in tubes, each containing 
10
7 
PBMC, according to different protocols:  i) For pre-saturation with mono-bulk 
vaccine antigens, PBMCs were first stained with Live/Dead Aqua (Invitrogen) 
diluted 1:500 in 100 µl, for 20 min in the dark. Then 50 µl of PBS containing 20% 
rabbit serum were added for further 20 min at 4°C to saturate Fc receptors. After 
two washes in 2 ml of PBS, PBMCs pellets were dissolved in 10 µl of PBS 
containing 30 µg/ml of vaccine subunit antigens (or 60 µg/ml in case of staining 
with 2 antigen baits) and incubated at 4°C in PBS. After 15 min, 10 µl of PBS 
containing 30 µg/ml (approximately 4 micromoles) of each 
fluorochrome-conjugated rHA bait were added, together with 50 µl of a cocktail of 
pre-titrated amounts of anti-CD20 PrCPCy5.5 (Becton Dickinson, clone L27), 
anti-CD27 PE (Becton Dickinson, clone L128) and anti-hIgG PacificBlue (Jackson 
ImmunoRes) monoclonal antibodies 1% FBS for 1 hour at 4°C. After two washes 
with 2 ml of 1% FBS/PBS cells were diluted in 1 ml of  5mM EDTA/PBS and 
acquired with the Canto II analyzer (Becton Dickinson, Pharmingen, San Diego, 
CA). ii) For neuraminidase pre-treatment, PBMCs pellets were diluted in 50 µl of 
PBS containing 0.1 to 5 M Type VIII neuraminidase from Clostridium perfringens 
(which cleaves α-2,3- α-2,6- and α-2,8-linked sialic-acid residues. # N5631 Sigma 
Aldrich), incubated for 30 min at 37°C and then washed 3 times with PBS. PBMCs 
were then stained as in i), but omitting the pre-incubation step with mono-bulk 
influenza antigens. iii) To saturate rHA binding sites for α2,6 linked sialic-acid 
residues, soluble sialopentasaccarides containing α2,6 linkage (provided by Dr. 






labeled-rHA for 15 min at 4° C. PBMCs were then stained as in i), but omitting the 
pre-incubation step with mono-bulk influenza antigens. iv) For pre-incubation with 
the Sambucus Nigra lectin (Vector Laboratories), PBMCs were stained as in i) 
adding as saturation agent 100 l of a solution of PBS containing 10 to 100 g/ml 
of the lectin for 15 min at 4°C, instead of mono-bulk influenza 
antigens.  Flow-cytometric analysis was performed using the FlowJo software 
(Treestar Inc.). For antigen-specific B-cell sorting, PBMCs from the same donor 
stained at 10
7
/tube were then pooled, diluted in 1 ml of 5mM EDTA/PBS and 
filtered through 30 m cup filcon (Becton Dickinson). Samples were maintained on 
ice until sorting. Sorting was performed in high purity mode by a FACS Aria 
instrument (BD Biosciences, San Jose, CA) equipped with the BD FACSDiva 
v6.1.3 software using a 70  µm nozzle operating at 70 psi. Sorting gates were 




 cells, unless differently 
specified. HA negative (HA
neg
) B cells and CD20 negative (CD20
neg
) cells were 




 B-cell cultures, 
respectively.  
ELISPOT 







 B-cells were cultured in vitro in 0.2 ml of 
complete medium (RPMI with 100 units/mL penicillin, 100 g/mL of 
streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, and 0.1 mM not 
essential amino acids, 5%FBS; Invitrogen) containing 2.5 g/ml of CpG (PRIMM, 
Milan, Italy) and 1000U/ml of IL-2 (Novartis). CD20- B-cells were added as 
feeders to HA
+
 B-cell cultures in variable ratios (from 1:30 to 1:200) to achieve a 
cell density of at least 10
6
/ml. After 5 days, cultured cells were washed 4 times in 
PBS, counted, diluted to equal concentrations in complete medium and plated in 
complete medium (200 l/well) in serial 2-fold dilutions in duplicate-triplicate 






anti-human IgG antibody. ELISPOT plates (MultiScreen HTS
TM
 HA, Millipore) 
were coated over night at 4°C with 100 g/ml of PBS containing 2.5 g/ml of an 
anti-human IgG (BD Pharmingen), or 10 g/ml of HSA (Sigma), H1N1 from 
A/California/07/2009 or A/Solomon Island/03/2006, or H3N2 from 
A/Brisbane/10/2007, or HA from B/Brisbane/60/2008. Following an overnight 
incubation at 37 °C and 5% CO2, the ELISPOT plates were washed 4 times with 
PBS, then 4 times with 0.05% Tween20/PBS. Spots of antibody secreting cells 
were revealed with biotin-conjugated mouse anti human IgG (Southern Biotech) 
diluted in 4% BSA/PBS for 4 hours at 37 °C, followed by horse radish 
peroxidase-conjugated Streptavidin (ENDOGEN). The reaction was then 
developed with 3-amino-9-ethylcarbazole (AEC, Sigma). Automated spot counting 
was performed using the UV Spot ELISPOT plate Analyzer (CTL) and the 
Immunospot software v5.09 (CTL).  







 B-cells were sorted into ice-cold 96-well PCR plates 
pre-filled with 4 μl/well of 0.5X PBS containing 10 mM DTT (Invitrogen), 8 U 
RNasin (Promega), 0.4 U RNAse Inhibitor (QIAGEN). After sorting, plates were 
sealed, centrifuged and immediately transferred at −80 °C. cDNA synthesis was 
performed adding 10.5μl mix to the 96-well plate containing the sorted cells. The 
mix contains 150 ng of random hexamer primers (Roche), 0.5% v/v Igepal 
(SIGMA CA-630), 1U RNAse Inhibitor (QIAGEN), 4U RNAsin (Promega), 
10mM DTT (Invitrogen), 0.5mM dNTP mix (Roche), 50U SuperScript III Reverse 
Transcriptase (Invitrogen), 5x Reverse Transcriptase Buffer (Invitrogen) diluted in 
nuclease free water (Invitrogen). The reaction was incubated at 25°C for 5’, at 
50°C for 60’, and at 70°C for 15’. For the 1
st
 PCR round 3.7 µl of cDNA template 
were mixed with forward primer mixes specific for the leader region and reverse 
primers specific for either IgH, IgK and Ig constant regions (20-21) in 3 different 
plates. For the 2
nd






mixed with nested forward and reverse primers mixes (20-21). Both PCR reactions 
were performed in 96 well plates (Eppendorf) in a total volume of 25 µl/well of 
nuclease free water containing 1x GoTaq Hot Start Green Master Mix (Promega) 
and 0.2 µM of each primer or primer mix. Each round of PCR was performed for 
50 cycles at 94°C for 30 seconds, 57°C (1
st
 PCR) or 59 °C (2
nd
 PCR) for 30 
seconds and 72°C for 55 seconds (1
st
 PCR) or 45 seconds (2
nd
 PCR). PCR products 
were separated on 2% agarose gels and analyzed for the presence of 350-400 
nucleotides products. Positive PCR products were purified from the wells of the 
plate using the QIAquick PCR Purification Kit (QIAGEN). PCR products were 
sequenced with the ABI 3730xl 96-capillary DNA analyzer (Applied Biosystems), 
using the second round PCR forward primer mix for the heavy chain products, the 
PanVK primer for the kappa light chain product, the second round reverse primer 
for the lambda light chain products. Sequences of the IgH/L V region were 
analyzed by IMGT/V-QUEST system.     
 
Statistical analysis 
A linear regression analysis was performed using the JMP 8.0.1 software to assess 
the presence of a linear correlation between frequency of H1
+
 IgG memory B-cells 
measured by flow-cytometry, or by conventional B-cell ELISPOT. Variability 
analysis was performed to compare the repeatability of the two assays. To avoid 
assuming that frequencies of amino acid replacements had a normal distribution, 





B-cells were analyzed by one-way Wilcoxon non-parametric test as implemented in 












Supplementary Figure 1. Expression of IgM, IgA and IgG BcR among H1
+
 B-cells in steady 
state. 
PBMCs from anonymous blood bank donors were pre-incubated with H3N2 subunit (from 
B/Brisbane/60/2008) and then stained with rH1 A/California/07/09 and mAbs anti-CD19, 
anti-CD27, anti-IgM and anti-IgG, or anti-IgA and anti-IgG. A. Dot plots gated on CD19
+
 B-cells 
showing the binding pattern of HSA or rH1 across mature memory (CD27
+
) and putatively naive 
(CD27
neg
) B-cells from donor #2. B. Dot plots showing the distribution of cells expressing IgA or 








 B cells. C. Frequencies of IgA, IgM and 
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Adaptive immune responses rely upon the establishment of a pool of antigen-
specific B cells and Plasmablasts. Both cell types are the result of an affinity 
maturation process that re-shapes the repertoire of their immunoglobulins in the 
regions that directly interacts with the antigen (the variable region), or determining 
different effector functions (the constant region). This study summarizes the results 
obtained from the dissection of the un-explored repertoire of Plasmablasts and 
factor H binding protein (fHbp) specific memory B cells following Meningococcus 
B vaccination. The analysis of Variable (V), Diversity (D) and Joining (J) 
rearrangements of fHbp specific B cells isolated from two vaccinated subjects, 
before and at different time points after vaccination revealed the preferential usage 
of particular genes. An accurate bioinformatic analysis to reconstruct the affinity 
maturation process encompassed by fHbp-specific Ig sequences has brought to the 
selection of 6 sequences from the repertoire of the two individuals. The 
corresponding antibodies have been tested for antigen binding specificity and 
affinity. Interestingly we found that 4 antibodies were binding fHbp antigen with 
























Effective vaccines act stimulating the immune system to recognize and remember 
the pathogens that they target, through the generation and the maintenance of a 
serological memory. Successful immune response may last for a lifetime after 
vaccination or infections [1, 2, 3]. Different hypotheses have been proposed to 
explain such durable responses and it is noteworthy that all these hypotheses rely 
upon the establishment of a pool of long-lived Antigen (Ag)-specific Plasmacells 
and Memory B cells (MBCs) [4, 5].  
Both cell types are the result of an affinity maturation process that re-shapes the 
repertoire of B cells responding to the eliciting antigen and generally occurs in 
specialized secondary lymphoid organs, also called germinal centers (GCs) [6]. 
Herein, activated B cells encompass somatic hypermutation (SHM), i.e. the 
introduction of point mutations, deletions and duplications in the germline 
sequence of V(D)J genes and class switch recombination (CSR) that initiates the 
gene-re-arrangements required to switch the immunoglobulin constant region from 
IgM to a different class (IgG, IgA or IgE) [7]. Following these events a multitude 
of clones, carrying modified immunoglobulin B cell receptors (BCRs) and thus 
differing in binding affinity to the antigen, are generated [8]. Finally, inside the 
GC, B cell clones that acquired improved affinity for the antigen achieve a 
proliferative advantage out-competing the others, which instead will die by neglect.  
B cell differentiation in response to vaccine antigens is considered classically to 
develop along two pathways; one leads rapidly to the appearance of clusters of 
Plasmablasts (PBs) secreting antibodies, and the second leads to the appearance of 
GCs and generation of a pool of MBCs.  Even if it is still controversial, there are 
several emerging evidences that Ag-specific PBs and MBCs undergo affinity 
maturation also without GC formation in extra-follicular pathways [9].  
Either following GC reaction or not, two populations of B cells carrying 






populate the human blood after infection or vaccination in different timeslots and 
with different kinetics. PBs, representing the early component of host defense, peak 
in the blood around day 8 after vaccination and return quickly to undetectable 
levels thereafter. Otherwise, Ag-specific MBCs circulate at enriched frequency in 
the blood peaking at 1 month after vaccination, and contracting slightly above or 
equal to baseline at later time points. The fascinating and still mysterious nature of 
these B cell populations makes the dissection of their repertoire of particular 
interest, especially in the vaccination field where the comprehension of the 
mechanisms able to induce a more affine BCR against the eliciting antigen could 
help in designing ad hoc vaccines able to stimulate particular and dedicated arms of 
the immune responses.  
Different are the studies that have been focused on the characterization of the 
repertoire of PBs isolated after vaccination [10, 11, 12] to measure effector recall 
memory responses, but really few studies have investigated the relationship 
between MBCs and PBs populations [13]. Due to the paucity of studies looking 
into this aspect of immune memory, it is still unclear whether PBs and MBCs 
originate from the same clones of B cells capable of binding to the antigens before 
vaccination, or instead the precursors of PBs and MBCs correspond to distinct 
group of clones. Also unclear is the clonal nature and relationship of MBCs 
recruited and circulating at different time points after vaccination. Two are the 
main works in literature that investigated changes at molecular level in 
Immunoglobulin (Ig) genes between PBs and MBCs isolated after vaccination [13, 
14]; both the examples refer to tetanus toxoid vaccination and revealed that a clonal 
relationship between PBs and MBCs could exist, especially suggesting that Ag-
experienced MBCs could be recruited in recall responses, becoming precursors of 
newly generated PBs and MBCs.  
In line with these observations, this study was designed to characterize at 






MBCs recruited in the interaction with the factor H binding protein (fHbp) antigen 
following Meningococcus B vaccination. We describe here the results obtained 
dissecting the BCR repertoire of both PBs and fHbp-specific B cells isolated ex 
vivo from human PBMC collected from two subjects before and at different time 
points after MenB vaccination. We compare the IgH and IgL repertoire of MBCs 
and PBs and we also compare the fHbp-specific repertoire of the two individuals. 
Finally, informatic analysis of the antibody heavy chain sequences from the two 
individuals allowed us to determine the lineage structure of the repertoire and to 



























Selection of two vaccinees based on their serological and cellular responses to 
the antigen 
To get a comprehensive picture of the dynamic changes in the repertoire of B cells 
responding to a vaccine antigen following vaccination, we took advantage of 
PBMCs samples collected during a Meningococcus B vaccine clinical trial. 
Enrolled subjects were healthy adults who received 3 doses of vaccine at 1 month 
interval and blood samples were collected at different time points after vaccination: 
day 0 (pre-vaccination), day 30 post-1
st
 dose, day 7, day 30 and day 202 post-3
rd
 
dose of vaccination. The PBs response was analyzed at day 7 post-3
rd
; Ag-specific 
MBCs were analyzed at all other time points. 
The antibody response against fHbp in plasma samples and the frequency of 
antigen specific MBCs and PBs in peripheral blood were measured at different 
timepoints after vaccination in 6 subjects. Notably, following vaccination all 
subjects showed an increase in the antibody titers against fHbp as compared to 
baseline, as well as an increase in the frequency of fHbp-specific B cells. 
Comparable levels of antibodies were found in all subjects, with two of them (sbj 
#1 and #2) showing a slightly higher titer. Figure 1 shows that IgG-switched 
memory B cells (IgG MBC) specific for fHbp were detectable in all subjects at 
baseline (mean frequency ranging from 0.00% to 0.06% of total IgG MBC). By day 
30 post 3
rd
 dose of vaccination, the frequency of fHbp-IgG MBC increased in all 
subjects (ranging from 0.14% to 0.71%) and was maintained above pre-vaccination 
level (range: 0.15% to 0.25%) at least until day 202 after 3
rd 
dose, in all but one 
subject. At day 7 post-3
rd
 dose the frequency of fHbp-IgG- PBs ranged from 1.46% 
to 11.35. Interestingly, we observed the highest frequency of fHbp-IgG-switched 
PBs in subjects #1 and #2 (11.35% and 8.9% respectively), who also showed the 






selected for further B cell repertoire analysis on the basis of their serological and 




























Figure 1_ Frequencies of IgG-switched memory B cells (IgG MBC) and PBs (IgG PBs) 
specific for fHbp detected in all subjects by Elispot. The frequency of fHbp-specific IgG 
MBC is expressed as percentage of total MBC producing antibodies in PBMC cultured with 
CpG and IL-2. Frequency of IgG PBs specific for fHbp is detected by ELISpot in resting 
PBMC collected at day 7 after 3
rd
 dose of vaccination. Results are expressed as number of 
antigen specific antibody secreting cells (ASCs) in 10
6
 PBMC. Each symbol represents an 


































































Ex vivo analysis of quantitative and phenotypic changes in the pool of fHBp 
binding B cells 
Following this preliminary analysis, in order to get a comprehensive picture of the 
quantitative, phenotypic and molecular changes of the repertoire of fHbp specific B 
cells induced by vaccination we identified and isolated PBs at day 7 post-3
rd
 dose 
of vaccination, as well as all B cells binding fHbp through their BCR directly from 
ex vivo PBMCs collected at day 0 (pre-vaccination), day 30 post-1
st
 dose, day 30 
and day 202 post-3
rd
 dose of vaccination (Figure 2).  
As shown in Fig.2A PBs were identified based on the differential expression of 
cluster differentiation marker, namely: CD3-, CD19+, CD20-, CD27++ and 
CD38++. To identify fHbp+ B cells we took advantage of the method previously 
developed by our group [15]. PBMCs samples were incubated with Alexa647 
tagged-fHbp or Alexa647 tagged-Human Serum Albumin (HSA) as bait and 
monoclonal antibodies against CD19, CD27, anti- IgG, IgA and IgD.  At baseline, 
both subjects had quite low numbers of CD19+ fHbp+ B cells with a frequency of 
0,05 and of 0,03 for sbj #1 and #2 respectively, comparable to the negative control 
(HSA). Vaccination induced a slight and gradual increase of the frequencies of 
circulating fHbp+ B cells in the course of vaccination. At day30 post1
st
 we 
observed a frequency of 0,09 and 0,05 for sbj #1 and #2 respectively. At day30 post 
3
rd
 we observed the higher frequencies of fHbp+ B cells with respect to other time 
points with frequencies of 0,15 and 0,1 for sbj #1 and #2 respectively. Interestingly, 
at day202 post3rd these frequencies were roughly maintained with a value of 0,16 
and 0,08 for sbj #1 and #2. Despite this slight increase in frequencies, we observed 
substantial changes in the circulating pool of B cell subsets recruited in the 
interaction with fHbp, as shown in Figure 2B and 2C. At baseline, the rare fHbp+ 
B cells identified were mainly naive or natural effector (CD27+ or CD27- IgD+) B 
cells. Starting from day 30 post-1
st
 dose to day 202 post-3
rd
 dose of vaccination, the 






IgG switched Ig BCR increased in both subjects, while  the naive and natural 


























Figure 2_Identification of Plasmablasts and fHbp specific B cells in ex vivo PBMCs 
samples of vaccinees. PBMCs samples collected from sbj#1 and #2 at day 0 (pre-
vaccination), day 30 post-1st dose, day 30 and day 202 post-3rd dose of MenB 
vaccination were incubated with fHbp Alexa647 and mAbs anti-CD19, anti-CD27 and  
anti-human IgG, IgA and IgD. PBMCs samples collected at day7 post-3rd dose were 
stained with mAbs anti-CD3, anti-CD19, anti-CD20, anti-CD27 and anti-CD38. A) Dot 
plots gated on CD19
+
 B-cells showing the distribution of fHbp+ B-cells from sbj#1 
across: the mature memory (CD27
+
) and putatively naive (CD27
-
) B-cell. B) and C) 
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Optimization of scPCR approach on memory B cells 
Both plasmablasts and B cells binding fHbp were sorted as single cells in 96-well 
plates and analyzed for the rearranged V(DH)J genes of their BCR. Different were 
the protocols available in literature to amplify VH-VL genes from single cells but 
overall the efficiency on memory B cells isolated from frozen hPBMCs ranged 
between 17-35% [15, 13]. Thus, before moving to clinical samples, we optimized 
the entire procedure of Ig-scPCR by designing reverse primers specific for CH-CK-
CL to be used in the retro-transcription reaction. We also designed new forward 
primers for Ig-nested PCR with a broader coverage of all VH and VL families’ 
genes and reverse primers specific for the constant region of heavy and light chains 
(Table 1). By applying this strategy to both PBs and fHbp-specific B cell lysates 
we successfully rescued the 60-80% of PCR products. The PCR efficiency was 
comparable in both cell types and improved in respect with the one obtained 
before. Furthermore, the use of reverse primers specific for the constant region of 
heavy and light chains in PCR allowed determining the Ig class of the expressed 
Igs (figure 3).  


















MenB vaccination induces Ig class switch and a preferential VDJ usage in the 
pool of Fhbp-binding B cells. 
We finally obtained 21 clones from day 0, 132 clones from day 30 post-1
st
, 105 
clones from day 7 post-3
rd
, 95 clones from day 30 post-3
rd
 and 94 clones from day 
202 post-3
rd
 from sbj#1.  From sbj#2 we obtained 25 clones from day 0, 59 clones 
from day 30 post-1
st
, 185 clones from day 7 post-3
rd
, 46 clones from day 30 post-
3
rd
, 205 clones from day 202 post-3
rd
. All sequences were analyzed with regard to 
their VH (DH) JH gene segment usage, CDR3 length and Ig class. For the majority 
of the sequences we were able to identify also the antibody class (figure 3). We 
found that at baseline both subjects had a pool of fHbp-specific B cells mainly 
composed by IgM natural effector B cells (88% and 80% of all the sequences in sbj 
#1 and #2 respectively) followed by IgA switched B cells (12 and16% of the 
sequences in sbj #1 and #2 respectively) and finally from IgG-switched B cells (0 
and 4% in sbj #1 and #2 respectively) (Fig.3A and 3B). Starting from day 30 post-
1
st
 to day 202 post-3
rd
 we observed substantial changes in the pool of fHbp-specific 
B cells. IgG-switched B cells begin to populate the antigen-specific B cell pool, 
increasing in sbj#1 from 12% at day 30 post-1
st
, to 47% and 51% at day 30 and at 
day 202 post-3
rd
, respectively, and in sbj#2 from 20% at day30 post 1
st
 to 52% and 
42% at day30 and day202 post 3
rd
. IgM natural effector, or IgM memory B cells 
decrease from approximately 80% at day 30 post-1
st
 to 46% at both day 30 and day 
202 post-3
rd
 for sbj#1. This latter phenomenon was also observed for sbj #2 were 
IgM+ B cells decrease from 63% at day30 post 1
st
 to 41% and 54% respectively at 
day30 and day202 post 3
rd
. A slight decrease was observed also for IgA-switched B 
cells in the course of vaccination (ranging from approximately 8% at day 30 post-
1
st
 to 7% and 3% respectively at day 30 and at day 202 post-3
rd
 for subj #1 and 
from 18% at day30 post 1
st
 to 7% and 4% respectively at day 30 and day202 post 
3
rd
 for sbj #2.   
 










In parallel we looked also at the VH repertoire of fHbp-specific B cells. The 
bioinformatic tool used for this study analyzed the sequences into their likely 
germline gene segments and assigned sequences to inferred clonotypes. For both 
subjects we observed at all time points after vaccination a strong contribution of the 
VH3 gene family (figure 4), followed by the VH1.  Looking at the individual gene 
segments, the most common VH gene at day 0 was VH3-74, followed by VH3-33 
and VH3-15. At the following time points after vaccination there was a different 
pattern of VH genes expressed by the pool of fHbp-specific B cells.  In particular, 
we observed the preferential expression of VH3-23 gene, followed by VH3-74, 
VH3-11, VH3-7 and VH1-18. Moreover, VH3-23 was most frequently rearranged 
with JH4, followed by JH6 (Figure 4). A total of 677 unique fHbp-specific 
sequences were isolated from both subject (342 and 335 sequences from sbj#1 and 
sbj#2 respectively)  from all time points before and after vaccination except for day 
Figure 3_Ig class distribution of Plasmablasts and fHbp-specific B cells. The Ig 
class of all sequences obtained from sbj#1 and #2 (A and B) was determined after 
sequence analysis. The percentage of IgM, IgA and IgG of fHbp-specific B-cells 
isolated from day0, day30post1,day30 and day202 post3 and for PBs isolated at 







7 post-3rd. The most common rearrangements VH3-23*04/JH6*02 and VH3-
23*04/JH4*02 were present in samples from three and four time points, 
respectively. This could suggest that a large part of the fHbp-specific B cells 
repertoire in each subject is shifting over time after vaccination. On the other hand, 
there is also a small part of this repertoire that comprises clones that could derive 












































































































Plasmablasts repertoire differs from fHbp-specific B cells repertoire. 
Plasmablasts were identified and isolated based on the differential expression of 
CD surface markers (CD3-, CD19+, CD20-, CD27++ and CD38++). Compared to 
the memory B cells, the pool of plasmablasts was more heterogeneous both in 
terms of Ig-class switch and VH-VL repertoire. Indeed, the majority of 
plasmablasts were composed by IgA-switched B cell clones (48 and 60% of the 
sequences in sbj #1 and #2 respectively), followed by IgG (37% of the sequences in 
both subjects) and in a smaller part also from IgM (15% and 3% of the sequences 
in sbj#1 and #2 respectively) (Figure 3). Looking at the repertoire we observed the 
expression of a broader spectrum of VH genes. For both subjects we observed a 
strong contribution of VH3 gene family, followed by VH4 (Figure 5). Even if 
VH3-23 was the most expressed gene, V(DH)J rearrangements seems to derive 
from different clones in respect to the ones observed in the pool of fHbp-specific B 
cells. This finding could suggest that different precursor clones of B cells are 
recruited to populate the pool of Plasmablasts or Memory B cells after GC 
selection and affinity maturation. However we should not exclude that due to the 
nature of the MenB vaccine that is composed by three different recombinant 
antigens, Plasmablasts population is basically the result of different effective 
vaccine antigen components-specific B cells. 
 





Figure 4_ Circos plot showing the VHDJH gene usage in fHbp-specific B cells. 
Circos plots were generated for fHbp specific cells isolated from each timepoint.  
On the right half of each plot each VH gene segment is shown in a different color. 
The left half of each plot shows different JH gene segments. The colored ribbon 



































Figure 5_ Circos plot showing the VHDJH gene usage in PBs. Circos plot 
were generated for PBs isolated from day7 post 3
rd
 dose of vaccination.  







Generation of Fabs specific for fHbp. 
One interesting question about the antibody repertoire in the compartment of 
antigen-specific BCR repertoire is if the most effective antibodies derive or not 
from positive selection in the GC reaction for higher affinity for the antigen, and 
possibly higher functionality. To answer this question we investigated the nature of 
the selection in this Ig sequences using dedicated software that relies on the 
assumption that affinity maturation strongly occurs along preferred paths in 
genotype space [16].  
Following computational analysis of the repertoire we selected 6 Ig variable 
sequences identified in the two subjects at different time points after vaccination 
following preferential paths of mutations and possibly undergoing affinity 
maturation to be cloned and expressed as a fragment-antigen binding (Fab 
fragment). To generate the respective Fabs, VH and VL fragments were cloned into 
vectors and then expressed in Rosetta2(DE3) (Merk Millipore) strain. After 
purification, the binding specificity of the Fabs to fHbp was measured by Gyrolab 
immunoassay to determine both binding and affinity of the selected antibodies for 
fHbp. As shown in Figure 6, 4 of the selected antibodies generated from fHbp-
specific B cells at different time points after vaccination were capable of binding 
the fHbp antigen, and all exhibited high binding affinities, with a W values ranging 

























































Figure 6_ Characterization of anti-fHbp human Fabs. Gyrolab immunoassays were 







The B cell repertoire is repeatedly shaped by the selection occurring in response to 
eliciting agents such as pathogens and vaccine antigens.  The selection acts on the 
variable region, in the V(D)J gene segments, introducing sequential changes and 
redefining the specificity against the antigen domains [8]. Moreover also the 
constant region is modified switching from IgD+IgM+ BCR to different Ig 
classess, to mediate a more effective response recruiting the exact arm of effectors 
to clear the eliciting agents [7].      
Different are the studies underlying the importance of dissecting the BCR 
repertoire of different B cell subsets following vaccination to get a comprehensive 
picture of the dynamics of the vaccine response. However,  few studies looked at 
the repertoire of both PBs and antigen-specific MBCs. So far, the majority of the 
studies have focused only on the analysis of PBs [11, 12].  
We dissected for the first time the variability among individuals in the breadth of 
the response to fHbp in terms of specificity, frequency and class of memory cells 
elicited by the multicomponent Meningococcus B vaccine.  we also profiled the 
longitudinal changes of the repertoire at different time points after vaccination.  
Two subjects were chosen among six vaccines, based on their serological and 
cellular responses to fHbp overtime after vaccination.  By measuring both the 
antibody titers versus fHbp in plasma samples and the frequency of circulating 
fHbp-specific MBCs and PBs in peripheral blood we observed that there were 
overall no significant differences in the frequency of fHbp+ MBCs among the six 
subjects. Nevertheless two subjects showed higher serological and cellular 
responses to fHbp at day 7 post-3
rd
 dose in respect to the other subjects. To dissect 
their VH and VL repertoire we isolated fHbp+ B cells by FACS at different time 
points before and after vaccination, and Plasmablasts at day7 post-3
rd
. Interestingly, 
we observed two main findings. Firstly, in the pool of fHbp+ B cells there are 






after vaccination, underlined by the preferential expansion of some VH gene 
families induced by the vaccine, namely VH3-23 gene, followed by VH3-74, VH3-
11, VH3-7 and VH1-18. Moreover we observed that starting from day30 post1
st
 
dose to day202 post 3
rd
 dose, the VDJ usage across fHbp+ B cells isolated from 
each timepoint was comparable with the most common rearrangements VH3-
23*04/JH6*02 and VH3-23*04/JH4*02 present in three and four time points, 
respectively. We did not observe the expansion of any particular clonal lineage but 
this could be due to the nature of the vaccine, being a multicomponent vaccine, or 
to the number of subjects and sequences analyzed. The approach used for the 
sequencing of the Ig genes has allowed also to gain the information on the Ig class 
of each single BCR expressed by the isolated fHbp+ B cells. By looking at the 
changes in frequencies of the different Ig classes identified longitudinally, it is 
clear that the antigen selects and models the specificity of the responding B cells 
also by inducing class switching from IgM, that represent at baseline on average 
the 85% of the repertoire reacting with fHbp to IgG at the peak of the response. In 
fact, unless carriage cases, vaccination should be likely the first encounter with 
these type B meningococcus antigens.  
The second important finding is that MBCs and PBs elicited by MenB vaccination 
seems to derive from different clones. Previous studies demonstrated that a clonal 
relationship could exist between Ag-specific MBCs and PBs suggesting an 
involvement of Ag-experienced memory B cells in refilling newly generated PBs 
and MBCs at recall responses [13]. However, our finding could be explained by the 
intrinsic heterogeneity of PBs population generated by the encounter with different 
antigens present in the multicomponent MenB vaccine. Since our comparison 
between PBs and MBCs is done by looking at the heterogeneous pool of PBs and 
the restricted repertoire of fHbp+ MBC cells we do not exclude that this could limit 






Finally it is noteworthy to underline that by performing a computational analysis of 
the fHbp specific repertoire of two individuals, and by looking at the changes of it 
at different time points after vaccination, it has been possible to identify six related 
VH sequences at different time points after vaccination, following a preferential 
paths of mutations. By expressing the corresponding antibodies we have formally 
demonstrated that four of them do actually bind fHbp, with a comparable high 
affinity. The similar sequence and affinity of the antibodies isolated by two 
different subjects might therefore by inferred to a maturation and affinity selection 
process preferentially induced by the vaccine antigen. 
Overall this type of dissection represents the first longitudinal and in depth analysis 
of the evolution of Ig-BCR response of fHbp+ MBCs and Plasmblasts following 
vaccination. We strongly believe that extending this approach to a large number of 
vaccinated subjects and moreover to large cohorts of vaccinees of different ages 
receiving different vaccine formulations could be helpful in understanding the 
evolution of the adaptive immune response, as well as in discriminating useless 
versus harming responses. This approach could be key for designing more effective 






















Materials and Methods 
 
Vaccination protocol and blood sample collection 
All subjects present in this study were enrolled in a study protocol and received 
three dose of the licensed vaccine against Meningococcus B strain. Blood and sera 
samples were collected at day0 (pre-vaccination), day 30 post-1st dose, day 7, day 
30 and day 202 post-3rd dose of vaccination once the informed consent had been 
obtained from the individuals and after approval by the local ethical committee. 
Gyrolab analysis to measure fHbp response in plasma samples and affinity of 
FAbs. 
Both Plasma samples of six subjects and Fabs generated after cloning were tested 
for their specificity to fHbp by Gyrolab assay. All plasma samples were diluted  
1:50 otherwise Fabs were tested at different concentration in order to calculate the 
affinity of each Fab. For both this assays, fHbp was biotinylated using use EZ-
Link® sulfo-NHS-LC-Biotin (Thermo Scientific, cat # 21335) and used at a final 
concentration of 100 μg/ml. Sera or Fabs bound to fHbp were detected by using an 
anti-human alexa647-conjugated IgG at a concentration of 25 nM. 
Analysis of fHbp-specific response of MBCs and PBs by ELISPOT assay 
The frequencies of fHbp-specific IgG and IgM have been determined in PBs and 
MBCs of six subjects by Elispot assay. PBs collected at day 7 post 3rd dose of 
vaccination were thawed, counted and diluted to appropriate concentrations in 
complete medium (RPMI with 100 units/mL penicillin, 100 µg/mL of 
streptomycin, 2 mM L glutamine, 1 mM sodium pyruvate, and 0.1 mM not 
essential amino acids, 5%FBS; Invitrogen) and directly plated (200 µl/well) in 
serial 2 fold dilutions in duplicate wells of ELISPOT plates pre coated with HSA, 
fHbp or both anti- human IgG and IgM antibodies. Otherwise resting MBCs, once 
thawed and counted, were firstly cultured in vitro with complete medium 






1000U/ml of IL 2 (Novartis), to induce the differentiation into antibody secreting 
cells. Following 5 days culture, cells were harvested and plated in ELISPOT plates 
as described with PBs. After incubation at 37°C and 5% CO2 for 2 hours, PBs or 
MBCs were removed and the plates were washed 6 times with 0.05% 
Tween20/PBS. Spots of antibody secreting cells were revealed with FITC-
conjugated anti human IgG (Fc) diluted 1:8000 and biotin-conjugated anti human 
IgM (Fc) diluted 1:1000 in 4% BSA/PBS. After an overnight incubation at 37 °C, a 
step with horse radish peroxidase conjugated Streptavidin (ENDOGEN) followed. 
The reaction was finally developed with 3 amino 9 ethylcarbazole (AEC, Sigma). 
Spots were counted automatically using the UV Spot ELISPOT plate Analyzer 
(CTL) and the Immunospot software v5.09 (CTL). 
Conjugation of fHbp with fluorochrome 
fHbp (Novartis vaccine antigen) and HSA (Sigma Aldrich) molecules were 
chemically labeled with Alexa Fluor 647 carboxylic acid succinimidyl ester 
(Molecular Probes, Invitrogen) following the manufacturer’s instructions. Briefly, 
each protein antigen was incubated with the dye at a molar ratio of 1:10 for 1 hour 
at room temperature and then loaded into a Zeba desalting spin column (Thermo 
Scientific) to remove unbound dye. The degree of labeling was determined 
following the manufacturer’s instructions, by measuring the absorbance of 
conjugated protein at the relevant wave length for each fluorochrome by 
spectrophotometry. Protein concentrations were calculated by the Bradford Assay 
(da vedere catalogo); the protein integrity was analyzed by SDS PAGE.  
Staining procedure for FACS analysis and sorting   
Frozen PBMCs were thawed at 37°C in PBS containing 2.5mM EDTA and 20 
µg/mL DNAse (Sigma Aldrich) and then divided into 2 ml Eppendorf tubes, each 
containing approximately 7x106 to 107 PBMC. Before incubating with the exact 
mix of Antibodies to differently identify Plasmablasts and fHbp-specific B cells, 






µl, for 20 min in the dark. Then 50 µl of PBS containing 20% rabbit serum were 
added for further 20 min at 4°C to saturate Fc receptors. After washing with 1,5 ml 
of PBS, PBMCs were stained differently based on the B cell population to identify. 
To identify PBs, PMCS were finally incubated with 50 µl of mix containing the 
following pre-titrated monoclonal antibodies diluted in 1% FBS: anti-CD19 APC 
(Becton Dickinson), anti-CD20 PrCPCy5.5 (Becton Dickinson), anti-CD27 –PE 
(Becton Dickinson), anti CD3-PB (Becton Dickinson) and CD38 Alexa700 
(ExBio). Otherwise, to identify fHbp specific B cells, PBMCs were firstly 
dissolved in 10 µl of PBS containing 10 µg/ml of Alexa 647-conjugated fHbp bait 
and then incubated with a mix of pre titrated amounts of monoclonal antibodies 
diluted in 1% FBS. The mix contained the following monoclonal antibodies: anti 
CD19 PrCPCy5.5 (Becton Dickinson), anti CD27-PE (Becton Dickinson), anti 
hIgG PacificBlue, anti IgA FITC and anti-IgD A700. The incubation was carried 
on for 1h at 4°C. After washing with 1,5 ml of 1% FBS/PBS cells were diluted in 1 
ml of BSA (vedere prodotto a 4°C) and stored on ice before acquisition at FACS 
Aria. FACS data of each samples were analyze using FlowJo software.  
Single PBs and fHbp-specific MBCs sorting and Ig RT-PCR 
PBs and fHbp-specific B cells were isolated as single cells respectively from day 7 
and from all others timepoints. The sorting was carried on in high purity mode by 
using a FACS Aria instrument (BD Biosciences, San Jose, CA) using a 70  µm 
nozzle operating at 70 psi. Two different sorting gates were established in order to 
isolate PBs and brilliant fHbp+ B cells. PBs were identified as CD3-CD19+CD20-
CD27++CD38+ B cells, otherwise fHbp+ specific B cells were isolated as fHbp+ 
CD19+ cells.  Cells were sorted as single cells in 96-well plates. The number of 
cells recovered from each timepoint was different based on the initial number of 
hPBMC after thawing and the frequency of Ag-specific B cells. Each well was 
previously pre-filled with 10 µl of a lysis buffer containing 1X RT-buffer, 0,7 µM 






prepared in a dedicated RNAse free area in order to avoid well to well 
contamination. After sorting, plates were sealed, centrifuged, labeled with subject 
code and vaccination time point and immediately transferred on dry ice and finally 
stored at -80°C. To generate the cDNA 5 µl of a mix containing Ig-gene specific 
primer (0,3 µM of each CH/CK/Cλ specific primer), 7,5 mM of MgCl2, 0,01 mM 
of DTT, 10 U of RNAse inhibitors and 50U of SSIII was added to each well. The 
RT-reaction was carried on at 50°C for 1h and at 85°C for last 5 minutes and 
cDNA was stored at -20°C if not used immediately after the RT reaction. Two 
rounds of Ig nested-PCR followed to amplify separately the heavy and the two light 
chains. To avoid well-to-well contamination all PCR mixes were prepared in an 
RNAse free area and the cDNA or PCR products were added in another laboratory. 
3,5 µl of Ig cDNA template were used as template for the first round of PCR in a 
final volume of 25 µl of a mix containing 1X PCR buffer, 0,3 µM of a set of IgH, 
Igκ or Igλ variable region primers and 0,5 µM  of either IgM, IgG and IgA or Igκ 
or Igλ constant region primers,  0,3 µM of dNTPs, 1X of Rediload, 1U of Pfx50 
DNA polymerase and 5% of DMSO to enhance the performance of the PCR 
reaction. 1st round PCR was performed at 94°C for 2 min followed by 35 cycles of 
94°C ×15s, 57°C ×60 s, 68°C x60 s, and one cycle at 68°C×7min. In the nested 2nd 
round nested PCR 3 µl of either IgVH or Igκ or Igλ PCR products were added to 
the 2nd round PCR mix composed by 1X PCR buffer, 0,3 µM of both IgH, Igκ or 
Igλ variable region primers and IgM, IgG and IgA or Igκ or Igλ constant region 
primers, 0,25 µM of dNTPs, 1X Rediload, 5% of DMSO, 1U of PfX50 Taq DNA 
polymerase.  The latter PCR was performed at 94°C for 2 min followed by 10 
cycles of 94°C ×15s, 57°C ×60s, 68°C x60s, 20 cycles at 94°C ×15s, 60°C ×60s, 
68°C x60s and one cycle at 68°C×7min. The sequences of primers are shown in 
table 1. 






2nd round PCR products were directly loaded to a 1,5% agarose gel 
electrophoresis, taking advantage of mixing the Rediload buffer in the PCR 
reaction mixture before cycling, and were visualized by exposure to UV light for 
the presence of 350-450 nucleotides products for IgH and Igλ and of 550-600 
nucleotides products for Igκ. Positive PCR products were purified with Agencourt 
Ampure beads (Beckman Coulter) and finally sequenced with the ABI 3730xl 96 
capillary DNA analyzer (Applied Biosystems). Two sequencing reactions were 
carried on for each PCR products by using 2nd round PCR forward primer mix in 
one reaction and 2nd round PCR reverse primer mix in the second reaction in order 
to have the entire IgH/κ/λ sequence. Sequences were analyzed by Sequencer 
software and the Ig-germline sequences were inferred by the dedicated Ig-
bioinformatics software. Sequences containing a stop codon or an out-of-frame 
rearrangement were considered as nonproductive and excluded from the analysis. 
The Ig class of each Heavy chain was determined by looking at the 
complementarity of the nucleotide sequence to the CH primer.   
Cloning of VH and VL and expression in ad hoc E.coli 
6 sequences of paired IgH and IgL were selected for cloning and expression. IgL 
PCR products were cloned by Polymerase Incomplete Primer Extension method 
(PIPE) (ref) in pETOmpHF vector, a modified pET21 (Novagen) containing a 5’ 
OmpA leader sequence. In parallel, also IgH PCR products were amplified and 
cloned in a modified version of pET22b (Novagen) containing the sequence 
encoding the CH1 region of human IgG. The resulting RBS-PelB-VH-CH1-6xHis 
cassette was amplified and sub-cloned by PIPE method in the corresponding light 
chain expression vector. All PCR reactions were performed with KAPAHiFi 
HotStart ReadyMix (Kapa Biosystems) at 95°C x5 min, 25 cycles at 98 °C x20 sec, 
55°C 30 sec, 72°C 30 sec/kb. Fabs were expressed in Rosetta2 (DE3) (Merk 
Millipore) strain in 50mL EnPresso B medium (BioSilta) supplemented with 






growth at 30°C and 160rpm, antibody expression was induced by the addition of 
1mM IPTG and incubation at 25°C at 160rpm for 24h. Bacteria were harvested by 
centrifugation (7650xg for 20 minutes) and protein extraction was performed by 
chemical lysis in CelLytic Express (Sigma-Aldrich). Pellets were re-suspended in 
10mL/g wet cell weight and incubated 15’ at room temperature. The suspension 
was then centrifuged at 10000xg for 20 min at 4°C and the clarified lysates were 
loaded on 0.5mL of manually packed Ni-NTA affinity resin (Qiagen) gravity 
columns equilibrated with 20 mM Tris-HCl, 300 mM NaCl, 10 mM imidazole, pH 
8. Columns were washed with 20 column volumes (CV) of equilibration buffer and 
with additional 20 CVs of 20 mM Tris-HCl, 300 mM NaCl, 30 mM imidazole, pH 
8. Bound protein was eluted in 3 CVs of 20 mM Tris, 300 mM NaCl, 200 mM 
imidazole, pH 8, concentrated and and subject to analysis by non-reducing SDS-
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The B cell repertoire is repeatedly shaped by the selection occurring in response to 
eliciting agents such as pathogens and vaccine antigens.  The selection acts both on 
the Variable region, in the V(D)J gene segments introducing sequential changes 
and redefining the specificity against the antigen domains, and in the Constant 
region determining the switch from IgD+IgM+ BCR to different Ig class to mediate 
a more effective response recruiting the exact arm of effectors to clear the eliciting 
agents.      
Different are the studies underlying the importance of dissecting the BCR 
repertoire of B cell subsets following vaccination to get a comprehensive picture of 
the dynamics of the vaccine response but a restricted number of them is looking at 
the repertoire of both the crucial components of the adaptive immune response: 
PBs and antigen-specific MBCs. So far, the majority of the studies have been 
focused only on the analysis of PBs.  This has been possible because plasmablasts 
peak 7-8 days post-vaccination in peripheral blood reaching relatively high 
frequencies, furthermore they are identifiable by flow-cytometry based on the 
expression of well-defined surface markers without the need of selection based on 
antigen specificity.  Otherwise the major obstacle in gaining insights on the 
antigen-specific MBCs population has been so far the lack of practical markers to 
identify rare antigen-specific MBCs within the bulk of MBCs present in ex vivo 
human PBMCs.  
In line with all the previous observations, my PhD research activity has been 
focused firstly on the isolation of rare circulating antigen-specific MBCs and 
amplification of their VH and VL genes. Finally this methodology has been used to 
draw a comprehensive picture of the evolution of the B cell repertoire in both 
MBCs and PBs at different time points after vaccination in subjects receiving 






At the time my PhD started, in our laboratory a methodology to identify rare MBCs 
specific for HA antigen from influenza virus was almost set up but there were no 
protocols available to retrotranscribe and amplify by PCR the VH and VL genes.   
To practice in the techniques required for amplification, sequencing, and cloning of 
paired VH/VL Ig genes from single cells by RT and Ig-nested PCR, I spent two 
weeks at the Novartis Institute for BioMedical Research in Basel. Thereafter I 
continued to dedicate my efforts in optimizing the strategy learned in Basel to 
amplify VH and VL genes as well as to exploit the tools developed at Novartis 
Vaccines to identify rare circulating B cells specific for both the influenza 
hemagglutinin antigen (HA) and other vaccine antigens such as MenB antigens.  
We demonstrated that B-cells carrying immunglobulin receptors specific for type A 
or B influenza HA could be identified in ex vivo PBMCs by using 
fluorochrome-tagged rHA as antigenic baits and unlabeled mismatched mono-bulk 
vaccine subunit antigens to block BCR-independent binding because of HA 
stickiness. We also showed that by combining rHA baits and monoclonal 
antibodies against surface B cell markers the method was suitable to analyze 
changes in the distribution of HA+ B cells across MBCs subsets at different 
maturation stages, including in subjects who did not experience a substantial 
increase in total number of HA+ MBCs. This observation provided a strong support 
to the feasibility of standardizing flow cytometry based assays for monitoring 
directly in PBMC samples ex vivo quantitative and phenotypic changes induced in 
the repertoire of HA+ B cells by influenza infection or vaccination. Moreover, we 
were able to sort arrays of single B cells with different HA binding specificities and 
to perform molecular cloning and in depth analysis of the VHVL Ig repertoires, as 
it was done with short lived plasmablasts circulating early after antigenic challenge. 
Since the methology was well established, we followed the same approach to 
dissect for the first time the individual variability in the breadth of the B cell 






against Meningococcus B. Specificity, frequency and class of the BCR of memory 
B cells elicited in response to fHbp have been described at different time points 
after vaccination in two individuals receiving the same vaccine.. 
We observed marked changes in the pool of fHbp+ B cells both in the usage of the 
VDJ genes among cells isolated before and after vaccination and in the type of 
class of Ig expressed by each cell. The results observed are compatible with the 
changes prompt by the antigen that selects and shapes the specificity of the 
responding B cells. Moreover we observed that the VDJ gene usage across fHbp+ 
B cells isolated at different timepoints was comparable, indicating a preferential 
expansion of selected VH gene families induced by the vaccine antigen. We did not 
observe the expansion of particular clonal lineages but this could be due to the type 
of vaccination and to the type of cells investigate. In fact, unless carriage cases, the 
vaccination should be the first encounter with this type of antigen.  
Moreover we found that there was not a relationship between the Ig repertoire 
identified in MBCs and PBs after MenB vaccination although previous studies 
demonstrated that a clonal relationship could exist between Ag-specific MBCs and 
PBs suggesting an involvement of ag-experienced memory B cells in refilling 
newly generated PBs and MBCs at recall responses. However, our finding could be 
explained by the intrinsic heterogeneity of PBs population generated by the 
encounter with different antigens present in the multicomponent MenB vaccine. 
Since our comparison between PBs and MBCs is done by looking at the 
heterogeneous pool of PBs and at the restricted repertoire of fHbp+ MBC cells we 
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